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Abstract 
The skeleton is a metabolically active organ that undergoes continuous 
remodelling throughout life. At the cellular level, bone remodelling is an 
organised process whereby osteoclasts remove old bone and osteoblasts 
replace them with newly formed bone. The osteoclasts and osteoblasts 
work together in a coupled manner within a so-called 'basic multicellular 
unit' (BMU). 
Bone remodelling helps to repair microdamages in bone matrix, preventing 
the accumulation of old bone. It also plays an important role in maintaining 
plasma calcium homeostasis. The regulation of bone remodelling is both 
systemic and local. The most important systemic regulator is parathyroid 
hormone (PTH), which has been used as a therapy to treat osteoporosis in 
clinics; however, the underlying mechanism by which PTH is regulated is 
still not clear. 
As far as local regulation of bone remodelling is concerned, the discovery 
of the RANK/RANKL/OPG pathway is significant to the understanding of 
the interaction between osteoclastic cells and osteoblastic cells in BMU. A 
large number of therapeutic drugs and other stimuli have been found to 
apply their effects via RANK/RANKL/OPG. 
Mechanical stimulus has significant influence on bone remodelling. Disuse 
or lack of loading causes bone remodelling with bone resorption 
dominating bone formation and thus a loss of bone mass or density. 
Conversely, overuse or increased loading causes bone mass or density to 
increase. Additionally, loadings with different characteristics such as 
frequency, number of loading cycles in a session and rest time between 
loading bouts affects bone remodelling differently. However, the 
underlying mechanisms are not fully understood despite a great deal of 
experimental work in this field. 
Pulsed electro-magnetic fields (PEMF) devices have been widely used in 
clinics to treat bone fracture non-union and shorten the recovery period of 
fracture. Despite the clinical success, it is still not clear how PEMF 
stimulus interacts with cells, factors or molecules that are involved in bone 
remodelling. 
This thesis will use a computational system biology approach to address the 
issues proposed above. Computational system biology is a systems biology 
approach that integrates experimental and computational research in order 
to understand complex biological systems such as bone remodelling. Based 
on the latest experimental results and mathematical advances, a 
mathematical model of bone remodelling at the cellular level is developed 
with PTH included. Building on this platform model, mechanical stimulus 
and PEMF are taken into account. Thus, their effects on bone remodelling 
and the underlying control mechanisms at the cellular level are investigated. 
The work in the thesis will further current understanding of bone 
remodelling at the cellular level. The quantitative analysis using our model 
will help pharmacological and non-pharmacological therapies 
developments, which eventually benefit patients who suffer from bone loss 
diseases such as osteoporosis. 
Keywords: bone remodelling; osteoblast; osteoclast, mathematical model; 
PTH, mechanical; PEMF; 
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Chapter 1: Introduction 
1.1 Basic Bone Biology 
Bone is a highly specialised support tissue that is characterized by its 
rigidity and hardness. It is composed of support cells (osteoblasts and 
osteocytes), remodelling cells (osteoclasts), non-mineral matrix of collagen 
and non-collagenous proteins (osteoid) and inorganic mineral salts 
deposited within the matrix. The major functions of bone are: to provide 
structural support for the body and protection of vital organs; to provide an 
environment for marrow (both blood forming and fat storage); and to act as 
a mineral reservoir for calcium homeostasis in the body. 
Bone cells that are concerned with production, maintenance and 
remodelling of the osteoid are (see Figure 1.1): 
• Osteoclasts: these cells are large, multinucleated cells, like 
macrophages, derived from the hematopoietic lineage. Osteoclasts 
Osteoclast Osteoblast &one Lining 
Cell 
Calcified 
Bone Matrix 
Osteocyte Osteoid 
Figure 1.1: Schematic illustration of main bone cells in a remodelling site 
function in the resorption of mineralised tissue and are found 
attached to the bone surface at sites of active bone resorption. Their 
characteristic feature is a ruffled edge where active resorption takes 
place with the secretion of bone-resorbing enzymes, which digest 
bone matrix. 
• Osteoblasts: these cells are derived from mesenchymal stem cells 
and are responsible for bone matrix synthesis and its subsequent 
mineralisation. In the adult skeleton, the majority of bone surfaces 
that are undergoing neither formation nor resorption (i.e. not being 
remodelled) are lined by bone lining cells (the inactive form of the 
osteoblast). 
• Osteocytes: these cells are osteoblasts that become incorporated 
within the newly formed osteoid, which eventually becomes calcified 
bone. Osteocytes situated deep within bone matrix maintain contact 
with newly incorporated osteocytes in osteoid, and with osteoblasts 
and bone lining cells on the bone surfaces, through an extensive 
network of cell processes (canaliculi). They are thought to be ideally 
situated to respond to changes in physical forces upon bone and to 
transduce messages to the osteoblastic cells on the bone surface, 
directing them to initiate resorption or formation responses. 
1.2 Research Background 
Osteoporosis is a condition in which the bones become fragile and brittle, 
leading to a higher risk of fractures than in normal bone1. It occurs when 
bones lose minerals, such as calcium, more quickly than the body can 
replace them, leading to a loss of bone mass or density. As a result, bones 
become thinner and less dense (see Figure 1.2), so that even a minor bump 
or accident can cause serious fractures. 
Osteoporosis is quite common in Australia, the data from the official 
government website of Osteoporosis Australia (www.osteoporosis.org.au) 
states that every five to six minutes, someone is admitted to an Australian 
hospital with an osteoporotic fracture. This is expected to rise to every 
three to four minutes by the year 2021, as the population ages and the 
number of osteoporotic fractures increases. 
Bone is a dynamic, living tissue; its shape and structure continuously 
evolve throughout life. It has the ability to change its structure by removing 
old bone and replacing it with newly formed bone in a local process called 
bone remodelling. Osteoporosis is the result of dysfunction of bone 
remodelling, which means with osteoporosis, the rate of bone loss is greater 
1 Definition from Osteoporosis Australia (www.osteoporosis.org.au) 
Figure 1.2: Comparison between normal bone matrix and osteoporosis in the human hip2 
than that of bone gain, which causes porous bone that breaks easily. 
Bone remodelling is a complex process performed by the coordinated 
activities of osteoblasts and osteoclasts. Together, these cells form 
temporary anatomical structures, called basic multicellular units (BMUs), 
which execute bone remodelling. The interactions between osteoblasts and 
osteoclasts, which guarantee a proper balance between bone gain and loss, 
is known as coupling [1]. 
2 Picture from http://www.halanmediacorp.eom/wp-content/uploads/2009/l 1/osteoporosis.jpg 
Specific regions of bone are targeted for remodelling due to structural 
microdamage, thus maintaining the mechanical strength of the skeleton 
(targeted remodelling) [2, 3]. In addition, bone remodelling plays a major 
role in mineral homeostasis, by providing access to stores of calcium and 
phosphate [4], In this case, bone remodelling occurs at random locations, 
so that every part of the skeleton is remodelled periodically (random 
remodelling) [2, 3]. 
The net amount of old bone removed and new bone restored in the 
remodelling cycle is a quantity called the bone balance. While coupling 
rarely is affected, bone balance can vary quite widely in many disease 
states; for example, in osteoporotic patients, resorption and formation are 
coupled but there is a negative bone balance, i.e. more bone is resorbed 
than is replaced by the typical BMUs. 
BMUs are constantly remodelling bone tissue in the growing, adult, and 
senescent skeleton. Most metabolic bone diseases appear when a 
biochemical or cellular link of this finely organised network is chronically 
disrupted, such as osteoporosis, hyperparathyroidism, osteomalacia and 
corticosteroid-induced osteopenia. Remodelling also permits the restoration 
of microdamage caused by fatigue and shock. This constant care of the 
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bone matrix prevents its premature deterioration and maintains its overall 
strength. 
Bone, being a major reservoir of body calcium, is under the hormonal 
control of Parathyroid Hormone (PTH) [5]. PTH is the most important 
hormone regulating calcium homeostasis and bone remodelling. Moreover, 
PTH is currently involved in numerous clinical trials as an anabolic agent 
for the treatment of low bone mass in osteoporosis [6]. Interestingly, the 
overall effect of PTH on bone mass depends primarily on its mode of 
administration; whereas a continuous increase in PTH levels decreases 
bone mass, intermittent PTH administration increases bone mass [7-11]. 
Despite many attempts to identify the source of these differential dosing 
effects on bone turnover, the precise mechanism remains elusive. 
Prevention and reversal of bone loss require a thorough understanding of 
the remodelling process in bone, and the mechanism of bone formation and 
resorption, including the actions of hormones such as PTH. 
Long-term physical activity on a regular basis plays a particularly 
important role in maintaining healthy bones. Exercise can maintain and 
increase bone strength by increasing bone mass or by changing bone 
structure at micro- and macro-levels. Two main types of exercises are 
beneficial to bone health: weight-bearing exercise and resistance exercise 
(lifting weights with arms or legs). 
Weight-bearing exercise involves any exercise that is performed while a 
person is standing so that gravity is exerting a force. Examples of weight-
bearing activities are jogging, walking, tennis, dancing, golf and netball. 
Activities that are high-impact, such as aerobics, running and jumping, 
have a greater effect on bone strength than 'low-impact' activities, such as 
walking and cycling. 
Resistance exercises, also called strength training, can also have a positive 
effect on the health of bones. The strong muscle contractions that are 
required to move a heavy weight place stress or strain on the bone to which 
the muscles are attached. When a bone is repeatedly strained (as also 
happens in regular exercise training), it responds by increasing bone mass 
to become stronger. 
Generally speaking, physical activities place mechanical loading on the 
skeleton and mechanical loading has profound influences on bone 
remodelling. Disused or reduced loading due to long-term bed rest, cast 
immobilisation or microgravity conditions (such as experienced by 
astronauts in a space station or shuttle) induces obvious bone loss and 
mineral changes. Conversely, overuse or increased loading has the opposite 
effect; in tennis players, the bones of the racquet arm display significantly 
greater bone mineral density and cortical bone content than the non-playing 
arm. Although there exists a great deal of general knowledge about the role 
of mechanical loading on bone remodelling, further understanding of the 
underlying mechanism is needed. 
Electro-magnetic field (EMF) devices have been widely used clinically for 
bone fracture healing (non-union or slow union), and some bone-related 
diseases such as osteoporosis and osteoarthritis for many years. The 
application of an EMF to stimulate osteogenesis is based on the idea of 
stimulating the natural endogenous streaming potentials in bone. In the 
beginning, current was applied directly via electrodes and was produced by 
forcing electric current through a wire coil placed over the fracture. 
Periodic changes of the current then produced the required EMF in bone 
through Faraday induction. The most effective medical devices used today 
are time-dependent EMF, especially pulsed EMF (PEMF), and the 
frequency range is 1-100 Hz. The physiological frequency range (8-30 Hz), 
which is caused by natural muscle contraction and the subsequently 
induced EMF in bone tissue is mostly used in clinical therapies. The 
osteogenesis effect caused by a PEMF device is of great significance to 
patients, especially those who have already undergone failed surgical 
intervention [12]. 
Based on random and prospective clinical studies, the Food and Drug 
Administration (FDA) USA approved PEMF as a safe and effective way to 
treat non-union and osteoporosis diseases [13, 14], although the specific 
molecular mechanism is not fully understood. 
In summary, the current understanding of bone remodelling is primarily 
based on experimental results in vivo and in vitro. A great deal of research 
has been conducted on the interactions of autocrine, paracrine and 
endocrine activities of receptors and ligands in bone remodelling, the role 
of bone cells involved in this process at the cellular and genetic level, and 
the influence of different stimuli and factors such as mechanical stimulus, 
PEMF and PTH on bone formation in bone remodelling. Based on these 
observations, many hypotheses have been proposed as to the role played by 
different signalling pathways and the communication between bone cells in 
bone remodelling. However, due to the complexity of the bone regulation 
system, which involves numerous factors and interactions, the 
understanding of the 'system behaviour' is still fragmentary. 
Mathematical modelling is a powerful tool to reduce ambiguity as to causes 
and effects in complex systems. It allows one to test various experimental 
and theoretical hypotheses that may be difficult (such as time- or money-
consuming) or impossible to test in vivo or in vitro. The development of a 
pharmaceutical treatment for bone diseases can also be enhanced by 
computational system biology that uses mathematical modelling to 
integrate experimental data into a system level model, enabling the various 
interactions to be efficiently and methodically investigated [15]. However, 
only a few mathematical models thus far have been proposed regarding 
bone remodelling [5, 6, 16-20]. 
In this thesis, in order to remove the limitations to generalisation with 
respect to causes and effects of bone remodelling under mechanical 
stimulus and PEMF at the cellular level, mathematical models are used to 
provide a dynamic, quantitative and systematic description of the 
relationships among interacting components of the biological system-bone 
remodelling at the cellular level. 
1.3 Aims and Organisation of the Research 
The major aim of this project is to develop a mathematical framework of 
the cell population dynamics model of bone remodelling under mechanical 
stimulus and PEMFs at the cellular level, based on the latest experimental 
findings and mathematical advances. Four steps have been taken in order to 
achieve this goal. First, a foundation model of bone remodelling at the 
cellular level is proposed in Chapter 3. In particular, this model 
incorporates the most important systemic hormone in bone remodelling— 
PTH and is able to simulate the anabolic effect of PTH when applied 
intermittently, which has been used as a therapy to treat osteoporosis in 
clinics. Second, based on this foundation model, the effect of mechanical 
stimulus on bone remodelling is investigated in Chapter 4. Third, a 
parametric study of the control mechanism of bone remodelling under 
mechanical stimulus is conducted in Chapter 5, based on the work in 
Chapter 4. Fourth, based on the foundation model and Chapter 5, the 
theoretical study of bone remodelling under PEMF at the cellular level is 
performed together with the control mechanism investigation in Chapter 6. 
Conclusions and future work are presented in Chapter 7. 
1.4 The Structure of the Thesis 
Chapter 1 introduces the basic bone biology related to bone remodelling in 
order to provide the entry knowledge needed to understand the work. It 
includes the structure description of bone and the principal cells involved 
such as osteoclasts, osteoblasts and osteocytes. 
The research background in Section 1.2 justified the need for this research, 
by introducing the common disease in Australia called osteoporosis, which 
is the result of the dysfunction of bone remodelling. The effects of 
mechanical stimuli and EMF on bone remodelling were then briefly 
introduced and will be discussed in detail in Chapter 2. 
In Chapter 2, bone remodelling is explained in detail, including the origin, 
definition, bone remodelling cycle, BMU and receptor activator of nuclear 
factor (NF)-Kb (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) 
pathway. In addition, a gap in the current literature is identified as a lack of 
mathematical modelling of bone remodelling. Bone remodelling under 
mechanical stimulus is followed, with details provided about the factors 
involved in this process such as frequency, number of cycles and their 
effects. Finally, the reason why mathematical modelling is needed is 
discussed. A similar method is also used in Section 2.3 of bone remodelling 
under PEMF. 
In Chapter 3, a theoretical model for simulating the effects of PTH on bone 
metabolism at the cellular level is developed. PTH therapy is introduced in 
Section 3.1, which includes PTH's interaction with RANKL and OPG, the 
interaction within the RANK/RANKL/OPG pathway, as well as a 
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convergence hypothesis and the description of the model structure together 
with the lineage of the osteoblastic and osteoclastic cells involved. 
In Section 3.2, the law of mass action is applied to model receptors and 
ligands interactions such as PTH with its receptor, RANKL with RANK 
and RANKL with OPG. Based on these receptors and ligands formulations 
and using balance equations, a series of ordinary differential equations 
(ODEs) are proposed to model the population of principal cells such as 
osteoblasts and osteoclasts included in the model. Finally, a series of results 
are provided in the form of figures then discussed in Section 3.4, including 
the coupling effect between osteoblasts and osteoclasts. 
Chapter 4 provides the mathematical modelling of bone remodelling under 
mechanical stimulus—one of the most important stimuli. Background 
knowledge such as the RANK/RANKL/OPG pathway and 
mechanotransduction of bone remodelling under mechanical stimulus are 
explained at the beginning of the chapter. In the mathematical model 
section, the Hill equation is used to model the stimulatory and inhibitory 
effects of ligand-receptor reactions. The balance equations are then used to 
describe the evolution of the number of osteoblastic and osteoclastic cells 
in each maturation stage. Finally, in the numerical investigation, the 
mathematical model developed is used to simulate the experiments and a 
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comparison of results between simulation and experiment is made to test 
the validity of the model. 
The parametric study of the control mechanism of bone remodelling under 
mechanical stimulus is conducted in Chapter 5. The mathematical model 
used is from Chapter 4, so its development is only briefly reviewed in 
Section 5.1. The justification of the existence of the control mechanism of 
bone remodelling is given in Section 5.2, followed by an explanation of the 
method of parametric study. Finally, the results of parametric study are 
presented by figures and tables, accompanied by discussions. 
Bone remodelling under electro-magnetic fields is discussed in Chapter 6. 
The PEMF's effects on bone remodelling are reviewed, supported by the 
experimental results from the literature. The model structure of bone 
remodelling under PEMF is proposed then the mathematical models are 
proposed accordingly in Section 6.1. A numerical investigation of the 
model is conducted in Section 6.2, including the cell concentration 
dynamics of active osteoclasts (OCA), active osteoblasts (OBA) and 
osteoblastic precursors (OBP), as well as factors such as OPG and RANKL. 
Similar to Chapter 5, the parametric study of bone remodelling under 
PEMF is provided in Section 6.3. 
Conclusions and future work are presented in Chapter 7. Supplementary 
information is given in Appendices A, B, C and D. 
Chapter 2: Literature Review 
The literature related to the research in this thesis is reviewed in this 
chapter, including the bone biology of remodelling, mathematical models 
of bone remodelling at the cellular level, experimental findings and 
mathematical models of bone remodelling under mechanical stimulus, and 
experimental results and mathematical models of bone remodelling under 
PEMF. 
2.1 Bone Remodelling 
Bone is a living organ that undergoes remodelling throughout life. 
Remodelling results from the action of osteoblasts and osteoclasts, which 
are two principal cell types found in bone, and defects such as 
microfractures are repaired by their coupling reaction [21]. The osteoblast 
produces the matrix, which becomes mineralised in a well-regulated 
manner. This mineralised matrix can be removed by the activity of the 
osteoclast when activated. In a homeostatic equilibrium, resorption and 
formation are balanced so that old bone is continuously replaced by new 
tissue, which is regulated by a variety of biochemical, mechanical and 
electro-magnetic factors. In 1963, Frost defined this phenomenon as bone 
remodelling [22]. 
For normal adults, there is a balance between the amount of bone resorbed 
by osteoclasts and the amount of bone formed by osteoblasts [23]. In this 
complex process, bone is remodelled by groups of cells derived from 
different sources, which are usually called BMUs [24], that follow an 
activation-resorption-formation sequence event. The BMU is a mediator 
mechanism bridging individual cellular activity to whole bone morphology 
[25]. 
There are four stages in the bone remodelling cycle (see Figure 2.1). This 
starts with resorption that activates multinucleated osteoclasts derived from 
bone marrow monocytes, which resorb a discrete area of mineralised bone 
matrix. After the completion of osteoclastic resorption, there is a reversal 
phase when subsequent osteoblast precursor cells, which can locally 
proliferate and differentiate into osteoblasts, migrate into the resorption 
lacuna and disclose the former osteoclastic activity. The formation phase 
follows with osteoblasts depositing new bone matrix, which is initially 
unmineralised and called osteoid, and in this way fills the resorption lacuna. 
After the completion of the formation stage, the quiescence stage starts 
whereby the osteoblasts embedded in osteoid mature into terminally 
differentiated osteocytes. The osteoblasts lying on the surface of the newly 
formed bone are lining cells. 
The assumption that a coupling mechanism must exist between bone 
formation and resorption was first reported in 1964 [26]. However, the 
exact molecular mechanism that describes the interaction between cells of 
the osteoblastic and osteoclastic lineages was identified approximately 30 
years later [27]. This breakthrough in the understanding of osteoclast 
differentiation and activation has come from the analysis of a family of 
biologically related tumour necrosis factor receptor (TNFR)/tumour 
necrosis factor (TNF)-like proteins: OPG, RANK and RANKL, which 
together regulate osteoclast function [23, 28, 29]. With the discovery of 
RANK, RANKL and OPG, a revolutionary understanding of 
osteoclastogenesis was born. The RANKL/OPG system is one of the major 
signalling systems that mediates bone remodelling. 
Osteoblasts have RANKL on their surface and via contact-dependent 
signalling, they activate RANK on the surface of osteoclast progenitors, 
resulting in osteoclast maturation and bone resorption. Osteoblasts also 
produce OPG, which acts as a decoy receptor, binding RANKL, thereby 
preventing it from binding RANK. Additionally, osteoblasts secret soluble 
RANKL, which can bind excess OPG, reducing its inhibitory effects. 
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Figure 2.1: Schematic diagram of bone remodelling cycle 
Bone remodelling is regulated by systemic hormones and local factors and 
it plays an important role in mineral homeostasis by providing access to 
stores of calcium and phosphate [4, 30]. PTH is the most important 
regulator of calcium homeostasis. It maintains serum calcium 
concentrations by stimulating bone resorption, increasing renal tubular 
calcium reabsorption and renal calcitriol production [21]. PTH is secreted 
in response to a drop in plasma Ca2+ levels. With the goal of maintaining 
plasma Ca2+, PTH increases bone resorption to release Ca2+ stored in bone. 
Acting on osteoblasts, PTH alters the expression of RANKL and OPG, 
leading to a large increase in the RANKL/OPG ratio, thus stimulating 
osteoclastogenesis and bone resorption [31, 32]. Most intriguingly, the 
overall effect of PTH on bone mass depends primarily on its mode of 
administration. Whereas a continuous increase in PTH levels decreases 
bone mass, intermittent PTH administration has an anabolic action on bone 
[7-11]. 
Bone is a rich source of growth factors, which have important actions in the 
regulation of bone formation and resorption. These factors are likely to be 
released locally from bone as it resorbs or by bone cells activated as a 
consequence of the resorption process. When it comes to the local 
regulation of bone remodelling at the cellular level, the 
RANK/RANKL/OPG pathway provides a clear picture of the control of 
osteoclastogenesis and coupling between osteoclastic and osteoblastic cells. 
It has been hypothesised that OPG and RANKL can be the mediators for 
the stimulatory or inhibitory effects of a variety of systemic hormones, 
growth factors, and cytokines on osteoclastogenesis. This is referred to as 
'convergence hypothesis' in which the activity of the resorptive and 
antiresorptive agents 'converges' at the level of these two mediators, whose 
final ratio controls the degree of osteoclast differentiation, activation and 
apoptosis [33]. The TGF-P superfamily may be particularly important in 
the coupling that links bone formation to bone resorption. Bone resorption 
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leads to the release of active TGF-(3 from bone and exposure of osteoblast 
precursors to active TGF-(3 proliferation. The potential interactions between 
those factors are complex, but it will be essential to unveil them to 
understand the local control of bone remodelling. 
After a thorough search through the literature, to the author's knowledge, 
only a few mathematical models thus far have been proposed regarding 
bone remodelling. Komarova et al. [17] presented a theoretical model of 
autocrine and paracrine interactions among osteoblasts and osteoclasts. 
Komarova et al. [18] also developed a mathematical model that describes 
the actions of PTH at a single site of bone remodelling, where osteoblasts 
and osteoclasts are regulated by local autocrine and paracrine factors. 
Potter et al. [19] proposed a mathematical model for PTH receptor (PTH1R) 
kinetics, focusing on the receptor's response to PTH dosing to discern bone 
formation responses from bone resorption. Lemaire et al. [6] incorporated 
detailed biological information and a RANK/RANKL/OPG pathway into 
the remodelling cycle; however, only the catabolic effect of PTH on bone is 
included in the model. Pivonka et al. developed an extended bone-cell 
population model based on the work of Lemaire et al. [6] to explore the 
model structure of cell-cell interactions theoretically [20], then investigated 
the role of the RANK/RANKL/OPG system in bone remodelling [15]. 
Incorporating the latest experimental findings and mathematical advances, 
a mathematical model of bone cell population dynamics at the cellular level 
[34] was developed and is discussed in Chapter 3. This model incorporates 
a different understanding of the RANK/RANKL/OPG pathway into the 
bone remodelling model, and is able to simulate PTH's anabolic effect 
observed in clinical trials. It is expected that the model concerning systemic 
and local regulation of bone remodelling will lead to new approaches in the 
diagnosis and treatment of skeletal disorders. In particular, this model will 
help to develop new therapeutic approaches at the molecular and cellular 
level based on the definition of abnormalities of the osteoblastic and 
osteoclastic lineage that lead to bone diseases such as osteoporosis. 
2.2 Bone Remodelling under Mechanical Stimulus 
Bone is a metabolically active tissue capable of adapting its structure and 
mass to the biological and mechanical environment and repairing damaged 
sections through remodelling. In particular, mechanical loading has 
significant influence on bone remodelling. Disuse or reduced loading due 
to long-term bed rest, cast immobilisation or microgravity conditions (such 
as experienced by astronauts in a space station or shuttle) induces obvious 
bone loss and mineral changes [35, 36], probably because of a lack of 
convective fluid flow in the canalicular network. Overuse or increased 
loading such as that which is experienced with weight lifting exercises 
causes damage to bone tissue, which in turn stimulates bone remodelling 
and eventually achieves bone gain. One of the important roles of bone 
remodelling is to replace and repair damaged bone tissue continuously. 
Osteoclasts start resorbing bone in response to signals that are as yet 
unknown but may include direct damage to osteocytes via micro-cracks in 
the bone matrix. 
The adaptive response of bone to mechanical loading is highly site-specific. 
This is clearly evident at the whole bone level, with only the bone that is 
actually loaded undergoing adaptation [37]. This concept is supported by 
much human research investigating skeleton health indices in athletes. This 
is especially noticeable in players of racquet sports such as tennis, as the 
bones of the racquet arm or dominant arm display significantly greater 
bone mineral density and cortical bone content than the non-playing arm 
[38, 39]. The site-specific depositing of new bone is functionally important. 
It puts newly formed bone where it is most required and increases bone 
strength in the resistible direction of loading, while not necessarily 
increasing the bone mass or density [38]. 
Experimental observations [39] show that in comparison with other organ 
systems, skeleton tissue is hypocellular and primarily composed of 
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extracellular matrix. Trabecular bone is a porous latticework of struts or 
plates of long bones, whereas cortical bone is a dense tissue of low porosity 
found in the diaphyses of long bones. The micro-structure of cortical bone 
is organised as a hierarchical arrangement of porosities, including a 
network of cellular spaces (lacunae), interconnections (canaliculi) and 
larger vascular (osteonal) canals. This spectrum of micro-architecture 
features implies the transformation of whole skeleton loading to localised 
changes in remodelling cycles. 
The current understanding of bone remodelling under mechanical stimulus 
is primarily based on experimental results in vivo and in vitro. A recent 
report [40] suggested that osteocytes are the professional mechanosensory 
cells of bone and the lacuno-canalicular porosity is the structure that 
mediates mechanosensing. It was also shown that the dynamic mechanical 
load causes fluid flow in the lacuno-canalicular network [41]. The 
experiments in vivo indicated that the fluid flow serves as the physical 
mediator of mechanotransduction of osteocytes [42]. It is the fluid flow 
shear stress [43-46] that stimulates osteocytes to produce signalling 
molecules within minutes [47] such as prostaglandins (especially 
prostaglandin E2-PGE2) [46-53] and nitric oxide (NO) [45, 49, 50, 54-56], 
which modulate the activities of osteoblasts and osteoclasts and furnish the 
transduction from mechanical stimuli to biochemical signalling [49], NO is 
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a strong inhibitor of bone resorption and acts by inhibiting the RANKL 
expression in osteoblast precursors and increasing OPG production in OBA. 
Consequently, it can decrease the RANKL/OPG ratio, reduce recruitment 
of osteoclasts and elevate bone formation [57]. Alternatively, PGE 2 has 
strong osteogenic effects, which contribute to increases in osteoblasts 
differentiation from marrow stromal cells through the EP 4 receptor [48, 50, 
58-60]. 
The literature demonstrates that Huiskes and his colleagues studied 
trabecular bone extensively, in aspects ranging from prediction of the 
development of trabecular architecture [61] to the effects of mechanical 
forces on the maintenance and adaptation of form in trabecular bone [62, 
63]. Based on the trabecular bone remodelling theory developed by 
Weinans et al. [64], Li et al. [65] developed a new trabecular bone 
remodelling model that could simulate both the underload and overload 
resorption that often occur in dental implant treatments. 
However, compared with trabecular bone, which represents 20% of the 
skeletal mass [21], even less theoretical work has been performed on 
cortical bone, which comprises 80% of the skeleton and has a high 
resistance to bending and torsion [21]. To the author's knowledge, only 
three papers that mathematically analysed cortical bone remodelling have 
been published. Two of them [66, 67] presented a mathematical model at 
the cellular level, only introducing magnitude of force and number of 
osteocytes to consider production of NO and PGE2. The third paper [68] 
proposed a macroscopic model to describe the time-dependent 
characteristics of the bone remodelling process, which is difficult to 
uncover in the microscopic mechanism. 
In Chapter 4 of the thesis, inspired by current advances in bone biology 
experiments and based on [20], this study's cell population dynamics 
model is the first to incorporate several new features that can provide a 
deeper understanding of the mechanical bone remodelling mechanism at 
the cellular level, such as the osteocyte being the physical mediator of 
mechanotransduction and the extended Hill equation. Quantitative analysis 
using this model provides an insight into the effects of mechanical loading 
on cortical bone remodelling. From a control theory perspective, it is 
expected that there are several control mechanisms working in bone 
remodelling, which is a complex system. Based on the model developed in 
Chapter 4, an extensive parametric study of the control mechanism is 
performed in Chapter 5. The identified control mechanisms represented by 
parameter combinations are believed to be able to further the understanding 
of mechanical bone remodelling, and eventually help researchers to 
develop combined pharmacological-mechanical therapies to cure bone loss 
diseases. 
2.3 Bone Remodelling under PEMF 
The use of electrical stimulation in bone dates back hundreds of years to 
when a patient with tibia non-union was successfully cured in 1812 [69]. In 
1957, Fukuda and Yasuda discovered the piezoelectricity of bone. When 
bone is under compression, an electronegative potential is induced, while 
an electropositive potential is produced by bone under tension [70]. In 1982, 
Fukuda hypothesised that the growth of bone was regulated to best resist 
external force, and the controlling signal seemed to be the electric potential 
generated by shear piezoelectricity in collagen fibres and/or streaming 
potential in canaliculae [71]. Those two discoveries raised the possibility 
that the behaviour of bone cells could be affected by an externally applied 
electrical stimulus [72]. In 1982, Bassett was the first to use a pair of 
Helmholtz coils to produce a magnetic field across a fracture site and 
enhance oeteogenesis [73]. Since then, several major forms of electrical 
stimulation have been reported to produce osteogenesis, including 
capacitively and inductively coupled electro-magnetic and direct current 
fields [74, 75]. In addition, intense research into electrically induced 
osteogenesis on bone has been conducted using these methods both in vivo 
and in vitro [34, 74, 76, 77]. The osteogenesis effect on bone could not 
only be used on long bone fractures [73], but could also be used in 
osteoarthritic joints [78] and osteoporotic bone [79], as well as in reversing 
femoral head necrosis and augmenting spinal fusions [80], 
The biological process involved in the osteogenesis of bone caused by 
PEMF devices is bone remodelling. At the cellular level, bone remodelling 
is an organised process whereby osteoclasts remove old bone and 
osteoblasts replace it with newly formed bone. The osteoclasts and 
osteoblasts work in a coupled manner as a BMU, which is a mediator 
mechanism bridging individual cellular activity to whole bone morphology 
[81] and follows an activation-resorption-formation sequence [23]. After 
the discovery of the RANK/RANKL/OPG pathway [82], there is a clearer 
picture regarding the control of osteoclastogenesis and bone remodelling in 
general. 
Bone cell differentiation and proliferation are important factors during bone 
remodelling and clinical PEMF devices have been shown to affect 
differentiation and proliferation of bone cells in vitro [83, 84]. Although it 
has been proposed that gap junctions, which are specialised intercellular 
junctions, are mediators of the PEMF-related cellular responses [83, 85-87], 
the underlying mechanism at the cellular level that regulates bone 
remodelling under PEMF remains poorly understood due to the 
inconsistent or even contradictory results from experiments. For example, 
cell proliferation, as assayed by cell number and H-thymidine incorporation, 
has been reported to increase, decrease, and remain unaffected by PEMF 
exposure. Similarly, the production of alkaline phosphatise has been 
reported to either increase or decrease following PEMF exposure. 
Although many in vitro and in vivo studies have been performed, the 
cellular mechanism by which PEMF affects bone remodelling is still 
elusive. To the author's knowledge, no study has been published about this 
research using a mathematical model. To clarify the underlying mechanism 
at the cellular level regulating PEMF's effect on bone remodelling, based 
on the cell population dynamics model [20] and the author's previous work 
[34, 88], the computational system biology method is used (see Chapter 6) 
with the purpose of better understanding bone remodelling under PEMF. 
The validated model generated using computational system biology can be 
used as a tool to reduce ambiguity as to the causes and effects in complex 
systems such as bone remodelling. In addition, it allows for the testing of 
various experimental and theoretical hypotheses 'in silico' [89], and more 
important pharmaceutical and clinical interventions on metabolic bone 
diseases. 
2.4 Summary 
In this chapter, bone remodelling was reviewed including the history of the 
term, the definition and the roles that PTH plays in the system. Bone 
remodelling under mechanical stimulus, one of the most profound stimuli, 
was reviewed in Section 2.2. Finally, bone remodelling under PEMF was 
reviewed in Section 2.3 along with the findings from experimental studies. 
Chapter 3: A Theoretical Model for Simulating the Effect of 
Parathyroid Hormone on Bone Metabolism at the Cellular 
Level 
PTH has been used clinically to treat bone loss diseases. Interestingly, 
when PTH is administered continuously, it causes bone loss; however, 
when PTH is applied intermittently, it causes bone gain in patients. The 
underlying mechanism of this phenomenon remains unclear although PTH 
has been approved by FDA as a therapy to treat osteoporosis. In this 
chapter, mathematical modelling of bone remodelling is developed then 
used to address this issue. 
3.1 Model Development 
The overall integrity of bone appears to be controlled by hormones and 
many other proteins secreted by both hemopoietic bone marrow cells and 
bone cells. There is both systemic and local regulation of bone cell function. 
PTH is the most important regulator of calcium homeostasis, which can 
stimulate bone formation when it is given intermittently and bone 
resorption when it is secreted continuously [90]. Moreover, PTH is 
currently involved in numerous clinical trials as an anabolic agent for the 
treatment of low bone mass in osteoporosis. Forteo (PTH 1-34) was 
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approved as an anabolic therapy by the FDA [91, 92]. The insulin-like 
growth factor (IGF) system is also important for skeleton growth, it is 
among the major determinants of adult bone mass through its effect on the 
regulation of both bone formation and resorption [93]. IGF-1 promotes 
chondrocyte and osteoblast differentiation and growth. It is also a pivotal 
factor in the coupling of bone turnover because it is stored in the skeletal 
matrix and released during bone resorption [94] and stimulates bone 
formation directly. 
PTH receptors are largely expressed on the osteoblastic surface [95, 96]. 
Quasi-steady state levels of plasma PTH, by binding these receptors, 
stimulates the production of RANKL and inhibits the production of OPG 
by osteoblasts [96-98], which causes an increase in activated osteoclasts 
(AOC) numbers. A direct effect of PTH on osteoblasts that are anti-
apoptosis has also been experimentally observed [95, 99]. 
As far as the local regulation of bone cell function is concerned, after the 
recent discovery of the RANK/RANKL/OPG system, there is a clearer 
picture regarding the control of osteoclastogenesis and bone remodelling in 
general. The main switch for osteoclastic bone resorption is the RANKL 
[100], a cytokine that is released by activated osteoblasts. Its action on the 
RANK receptor is regulated by OPG, a decoy receptor, which is also 
derived from osteoblastic lineage-preosteoblasts. Osteoclast-to-osteoblast 
cross-talk occurs mostly through growth factors, such as transforming 
growth factor-P (TGF-f3), which are released from the bone matrix during 
resorption. 
The opposite phenotypes of OPG overexpression or with RANKL deletion 
mice (osteopetrosis) and OPG-deficient or with RANKL overexpression 
(osteoporosis) have led to the hypothesis that OPG and RANKL can be the 
mediators for the stimulatory or inhibitory effects of a variety of systemic 
hormones, growth factors and cytokines on osteoclastogenesis [21]. This is 
recently referred to as 'the convergence hypothesis' in that the activity of 
the resorptive and antiresorptive agents 'converges' at the level of these 
two mediators, whose final ratio controls the degree of osteoclast 
differentiation, activation and apoptosis [33]. 
The logical structure of the model is presented in Figure 3.1, which shows 
the simplified lineages of osteoblasts, osteoclasts and their interactions. 
The previously described BMU comprises a collection of different cell 
types with different origins. The osteoclast teams that line the cutting cone 
are derived from hematopoetic stem cells residing mainly in the marrow 
and spleen. Osteoclastogenesis begins when a hematopoetic stem cell is 
Apoptotic Osteoclast 
Figure 3.1: Schematic representation of the structure of the model |34]. The solid arrows with a (+) 
or (-) next to them represent a stimulatory or inhibitory action by the factor. The thin frame 
squares indicate types of cells that are included in this model 
stimulated to generate mononuclear cells, which then become committed 
preosteoclasts and are introduced into the blood stream. This step requires 
expression of the Ets family transcription factor PU.l and macrophage 
colony stimulating factor (M-CSF) [101, 102]. The circulating precursors 
exit the peripheral circulation at or near the site to be resorbed, and fuse 
with one another to form a multinucleated immature osteoclast. Fusion of 
the mononuclear cells into an immature osteoclast requires the presence of 
M-CSF and RANKL, a tumour-necrosis factor family member [103]. 
RANKL interacts with a receptor on osteoclast precursor called RANK. 
Further differentiation of the immature osteoclast into mature and AOC 
occurs only under the continued presence of RANKL [104]. The 
RANK/RANKL interaction results in activation, differentiation and fusion 
of hematopoietic cells of the osteoclast lineage so that they begin the 
process of resorption. Further, it prolongs osteoclast survival by 
suppressing apoptosis [105]. 
Osteoblast development follows a different course, beginning with the local 
proliferation of mesenchymal stem cells residing in the marrow, which can 
also give rise to other types of cells such as myocytes, chondrocytes and 
adipocytes [106]. Proliferating precursors are pushed toward the 
preosteoblasts—responding osteoblasts (ROB) under the complex effects 
of specific factors such as PTH and TGF-(3 [106]. After further 
differentiation, ROB mature to AOB, which are responsible for bone 
formation. Eventually, osteoblasts die or transform to either lining cells or 
osteocytes [107]. 
Bone matrix is the largest source of TGF-p in the body [108]. TGF-(3, as 
well as growth factors and specific components embedded in the bone 
matrix, are released by osteoclasts during bone resorption [109]. TGF-(3's 
effect on osteoblasts is bi-directional, depending upon the state of 
maturation of the osteoblasts [6]. On one hand, TGF-p has the potential to 
stimulate osteoblast recruitment, migration and proliferation of osteoblast 
precursors (meaning ROBs in this study's model) [110]. On the other, 
TGF-J3 inhibits terminal osteoblastic differentiation into AOBs [111]. TGF-
P is also known to induce osteoclast apoptosis [108, 112]. 
3.2 Mathematical Formulation 
In the model shown in Figure 3.1, cellular interactions are performed via 
the activation of cell receptors. The receptors bind with molecules secreted 
by other cell types called paracrine, with molecules secreted by the same 
cell called autocrine or with other transmembrance molecules via direct 
cell-to-cell contacts. The different cell types represented in the model 
respond to the activation of their receptors by producing new molecules, 
differentiating or dying [6]. The mathematical formulation of the model is 
primarily influenced by physiological events involving receptor binding 
and intracellular signalling modelling [113, 114]. Applying the law of mass 
action [6] that is used to describe the reactions of receptors and 
corresponding ligands including PTH (P) with its receptor (Pr,), RANKL (L) 
with OPG (O), RANKL (L) with RANK (K) and IGF (I) with its receptor 
(IR). 
dP_ 
dt 
(3.2) 
— = pa-k]0-L + k2-0»L-dl 
dt o 
(3.3) 
^ = krO-L-k2.O.L (3.4) 
— = pL-ki-OL + k1-O^L-ki-K-L + k,K*L-dl dt 
(3.5) 
(3.6) 
The large dot above represents a receptor-ligand complex, while the small 
dot stands for the multiplication. The details of the meaning and values of 
the parameters and coefficients can be found in Appendix A. 
This model proposes that the cell proliferation rate is proportional to the 
receptor occupancy [6]; this rule is applied to other types of cell responses 
besides cell proliferation. Moreover, the anti-proliferative cell responses 
are inversely proportional to the receptor occupancy. Consequently, the 
production rate of OPG (PQ) is down-regulated by PTH and up-regulated 
by TGF-(3, the expression of PQ is: 
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where the proportion of occupied PTH receptor is: 
\ p » p \ p + p ° 
7 Z U 
Ur/kp+Sp/kp 
P + P* V Ip/K+kJk, 
(3.8) 
Applying the same rule as obtaining P(), the following can deduced [6]: 
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The entering flow into the ROB compartment depends on the mesenchymal 
stem cells response to c binding. This response is represented by a 
proportionality relationship with the TGF-(3 receptor occupancy n c : 
D R - n c = D R 
C + C° 
c + c s (3.12) 
The outgoing flow of the ROB compartment is also the feeding flow to the 
AOB compartment. Under the influence of TGF-(3 and IGF, which inhibit 
and stimulate AOB production respectively: 
DB-R-
a i N 
— + 71 (3.13) 
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RANK-RANKL binding promotes the differentiation of mesenchymal stem 
cells into AOC [6], the differentiation rate is proportional to the RANK 
occupancy ratio nL: 
DC-NL=DC 
K»L 
K 
(3.14) 
TGF-(3 induces osteoclast apoptosis via binding to specific receptors and 
under the influence of RANKL, this phenomenon is then represented as: 
(3.15) 
The equations governing the evolution of the number of cells in each 
compartment are simply balance equations [6], which means each cell 
compartment is fed by an entering flow and is emptied by the outgoing 
flow of differentiated or apoptotic cells: 
™ = DR-TTC-DB-R- - + 7I, 
\nc 
(3.16) 
m 
dt B 
- + 7T, 
X M 
- ( k B - n P ) - B (3.17) 
(3.18) 
The rate of bone resorption and formation is assumed proportional to the 
numbers of osteoclasts and osteoblasts respectively: 
- = -m,-C + m2-B (3.19) 
dt 
where Z is total bone mass. Noting that at equilibrium, where the 
simulation starts, the numbers of AOB, AOC and ROB do not change with 
time; solving the following three equations can determine the initial values 
ofB, Cand R: 
0 = D R - T T C - D B - R 
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(3.20) 
(3.21) 
(3.22) 
Values of model parameters and initial conditions of variables are listed in 
Appendix A. Model equations (3.16) to (3.19) are then solved using 
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numerical integration by a fourth Runge-Kutta algorithm implemented in 
Matlab. This is performed in the next section. 
3.3 Results and Discussion 
To demonstrate the tight coupling between osteoblast and osteoclast, this 
system was computationally perturbed by adding or removing specific cells 
such as AOB and AOC. The results are displayed in Figures 3.2-3.7. 
t/days 
Figure 3.2: The AOBs are added at a constant (0.0001 pM/day) rate for 60 days from start. From 
top to bottom, dash curves, dot curves and solid curves represent AOB, ROB and AOC respectively 
t /days 
Figure 3.3: The effect of adding AOBs at a constant rate (0.0001 pM/day) on bone mass. Changes in 
bone mass are expressed as a percentage of initial bone mass (100%) 
It is evident from Figures 3.2 and 3.3 that adding AOBs can initiate a 
remodelling cycle from an initial stable state. It is also evident that the 
number of AOC decreases in the first 7 days, then increases to the initial 
value, while the number of AOB increases as expected. This means that the 
direct administration of AOBs does not have a strong stimulatory effect on 
AOC, which is consistent with experimental observation [103]. Figure 3.3 
clearly displays that bone mass increases with the administration of AOBs 
and rises a little more slowly after AOB injection ceases. 
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Figure 3.4: The AOCs are added at a constant rate (0.001 pM/day) for 60 days from start 
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Figure 3.5: The effect of adding AOCs at a constant rate (0.001 pM/day) on bone mass 
Figure 3.4 shows that the administration of AOCs initiates a remodelling 
cycle and its number remains almost unchanged from approximately the 
seventh day to the 60th day. It also exhibits a strong and immediate 
stimulatory effect on ROBs (top dash curve), which means that the number 
of ROBs increases immediately with the injection of AOCs and decreases 
to the initial level after stopping the injection of AOCs. The response of 
AOBs to the administration of AOCs is to slow down and delay until the 
injection of AOCs stops. It can be observed from Figure 3.5 that the 
amount of AOBs that are responsible for producing bone mass begins to 
increase quickly, which accounts for the increase of bone mass after the 
60th day. 
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Figure 3.6: The ROBs are added at a constant rate (0.0001 pM/day) for 60 days from start 
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Figure 3.7: The effect of adding ROBs at a constant rate (0.0001 pM/day) on bone mass 
An interesting phenomenon was observed when ROBs are administered to 
the system. The AOBs increase in number along with an increase in ROB, 
whereas the number of AOCs decreases for approximately the first seven 
days and then remains unchanged at a particular level, which is lower than 
the initial state, until the 60 t h day. After 60 days, it equilibrates to an even 
smaller value as illustrated in Figure 3.6. Consequently, it is reasonable that 
the bone mass continues to rise, as shown in Figure 3.7. This observation 
may have the potential to be exploited as a therapeutic target for metabolic 
diseases. 
The only systemic hormone considered in the model is PTH. As mentioned 
earlier, intermittent infusion of PTH has potent anabolic effects on bone 
mass. To test the anabolic action of PTH in the model, the hormone is 
delivered at a steady rate of 3000 pM/day for 60 days. As can be observed 
from Figure 3.8, the number of AOC increases with the infusion of PTH, 
then drops quickly in response to the cessation of PTH administration. The 
response of AOB to the intermittent injection of PTH is relatively slow; the 
number of AOB continues to increase even after the PTH administration, 
which is the key to the final increase in bone mass (see Figure 3.9). This is 
in agreement with the experimental observation [91]. 
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Figure 3.8: The responses of AOC, AOB and ROB to the intermittent administration of PTH for 
the first seven days 
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Figure 3.9: The effect of intermittent administration of P T H for the first seven days on bone mass 
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Figure 3.10: The responses of A O C , A O B and R O B to the continuous administration of P T H for 
120 days 
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Figure 3.11: The effect of continuous administration of PTH for 120 days on bone mass 
As expected under the continuous administration of PTH, bone mass 
continually decreases, as shown in Figure 3.11. This simulation is in good 
agreement with the experimental results [115, 116]. It can be observed 
from Figure 3.10 that the response of AOC, ROB and AOB are affected by 
the PTH. In particular, the number of AOC increases promptly as PTH is 
injected, followed by a minor drop, and then keeps rising at a slower rate. 
However, the number of AOB increases only slightly and at a very slow 
rate over the first 120 days. Through the direct stimulatory effect of TGF-p 
released by AOC, the number of ROB increases at a higher rate than the 
AOB. 
3.4 Summary 
In this chapter, the proposed model has taken into consideration the latest 
progresses in the bone biology of remodelling using appropriate parameters 
and equations, such as the law of mass action, in order to provide the 
underlying mechanism for a variety of complex experimental observations. 
Importantly, the simulation results using this model are consistent with all 
the experimental findings. In particular, the tight coupling behaviour 
between osteoblasts and osteoclasts, which is the key in bone remodelling, 
is well explained by the model. In addition, the theoretical simulation is in 
good agreement with the widely used PTH therapy for osteoporosis 
approved by the FDA. 
Chapter 4: Bone Remodelling under Mechanical Stimulus 
Mechanical loadings have profound influences on bone remodelling. 
Disuse or reduced loading due to long-term bed rest for example, 
experienced by fracture patients, induces obvious bone loss and mineral 
changes. Conversely, overuse or increased loading has the opposite effect; 
in tennis players, the bones of the racquet arm display significantly greater 
bone mineral density and cortical bone content than the non-playing arm. 
Although a large amount of general knowledge regarding the role of 
mechanical loading in bone remodelling has been gained from experiments, 
further quantitative understanding of the underlying mechanism is still 
needed. 
4.1 Model Development 
4.1.1 RANK/RANKL/OPG Signalling Pathway 
The assumption that a coupling mechanism must exist between bone 
formation and resorption was first articulated in 1964 [22]. The exact 
molecular mechanism that describes the interaction between cells of the 
osteoblastic and osteoclastic lineages was identified over thirty years later 
[82]. Recent breakthroughs in the understanding of osteoclast 
differentiation and activation have come from the analysis of a family of 
biologically related TNFR/TNF-like proteins: OPG, RANK and RANKL, 
which together regulate osteoclast function [23, 28]. With the discovery of 
RANK/RANKL/OPG, a revolutionary understanding of osteoclastogenesis 
was born. 
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Figure 4.1: Illustration of the bone cell model with RANK/RANKL/OPG signalling pathway, PTH 
and dual action of TGF-p. A (+) or (-) symbol beside a factor represents a stimulatory or inhibitory 
action by the factor 
As far as the local regulation of bone cell function is concerned, after the 
recent discovery of the RANK/RANKL/OPG system, there is a clearer 
overall picture regarding the control of osteoclastogenesis and bone 
remodelling. The main switch for osteoclastic bone resorption is the 
RANKL [100], a cytokine that is released by preosteoblasts [20]. Its action 
on the RANK receptor is regulated by OPG, a decoy receptor, which is also 
derived from osteoblastic lineage-active osteoblasts [20]. Osteoclast-to-
osteoblast cross-talk occurs mostly through growth factors, such as 
transforming growth factor-P (TGF-(3), which are released from the bone 
matrix during resorption. The RANK/RANKL/OPG signalling pathway 
between osteoblasts and osteoclasts, PTH and the dual action of TGF-[3 is 
illustrated in Figure 4.1. 
4.1.2 Mechanotransduction in Bone 
The majority of the cells of bone tissue, some 95% in the adult skeleton, 
are osteocytes, lying within the bone matrix, and bone lining cells, lying on 
the bone surface [117]. Both osteocytes and bone lining cells are terminally 
differentiated osteoblasts and have long been considered as metabolically 
inactive, with limited roles in bone biology. However, osteocytes remain in 
contact with the bone surface cells and with neighbouring osteocytes via 
long slender cell processes that connect by means of gap junctions [118, 
119]. Consequently, their abundance and connectivity make them a three-
dimensional network for sensing mechanical strains. Recent work [40] 
demonstrates that osteocytes are the professional mechanosensory cells of 
bone and lacuno-canalicular porosity is the structure that mediates 
mechanosensing. 
It has also become clear that dynamic mechanical load causes fluid flow in 
the lacuno-canalicular network [41]. Experiments in vivo [42] have 
indicated that this fluid flow serves as the physical mediator of the 
mechanotransduction of osteocytes and it is the fluid flow shear stress [43] 
that stimulates osteocytes within minutes to produce signalling molecules 
[47] such as prostaglandins (especially PGE2) [46] and NO [45]. These 
modulate the activities of osteoblasts and osteoclasts, thus completing the 
transduction from mechanical stimuli to biochemical signals [49]. NO is a 
strong inhibitor of bone resorption and acts by inhibiting RANKL 
expression in osteoblast precursors, while increasing OPG production in 
OBA, thereby decreasing the RANKL/OPG equilibrium and leading to the 
reduced recruitment of osteoclasts and positive bone formation [57]. 
Alternatively, PGE2 has strong osteogenic effects, which contribute to 
increases in osteoblast differentiation from marrow stromal cells through 
the EP4 receptor [58]. 
4.2 Mathematical Model 
The schematic diagram of the mathematical model structure of mechanical 
loading-caused bone remodelling is shown in Figure 4.2. 
In biochemistry, the Hill equation is used to describe the fraction of the 
macromolecule saturated by a ligand as a function of the ligand 
concentration; it is used in determining the degree of cooperativity of the 
ligand binding to the enzyme or receptor. It was originally formulated by 
Hill in 1910 [120] to describe the sigmoidal 02 binding curve of 
haemoglobin: 
L" L" e=——=—-— (4.1) 
where 6 is the fraction of ligand binding sites filled, L is the ligand 
concentration, Kd is the apparent dissociation constant derived from the 
law of mass action, KA is the ligand concentration producing half 
occupation and n is the Hill coefficient. 
In cell biology, cell responses such as differentiation, proliferation and 
apoptosis are all related to various ligand-receptor reactions of which some 
are stimulatory and others are inhibitory [20]. In modelling cell responses, 
the Hill equation is often used to describe the molecular input function. The 
activation (act) and repression (rep) forms of the Hill equation [121] for the 
production rate of a new cell or molecule are [20]: 
(4.2) 
1 + -
(4.3) 
K. 
where x* is the active form of concentration x , which is a ligand that 
governs the production of a cell or molecule z through binding to its 
receptor on cell; p is the maximal production rate of z, and Kx and K2 are 
activation and repression coefficients. It has been assumed that the Hill 
coefficient equals one. In this model, the Hill equation is extended to the 
case in which two ligands (x and y ) both affect the production of z 
through binding to their respective receptors on the same cell. Then the 
production rate of z can be expressed as: 
where kx and ky are the relative influence of ligands x and y respectively, 
as a percentage in the cellular process, and kx+ky= 1. 
For convenience, in the following related formulation, the abbreviated 
forms are used for the factors involved. As in Figure 4.1, OBU was used 
f { x , y ) = p{kx-Uitlrep+ky.U:alrep) (4.4) 
for uncommitted osteoblastic progenitors, OBP for preosteoblast, OBA for 
mature osteoblast, OCP for osteoclast precursor, OST for osteocyte and 
OCA for active osteoclast. RL is used for RANKL, RK for RANK, T(3 for 
TGF-J3 and P2 for PGE2, while OPG, NO and PTH remain unchanged. 
The equations governing the evolution of the number of osteoblastic and 
osteoclastic cells in each maturation stage are simply balance equations [6], 
which means that each cell stage is fed by an entering flow and is emptied 
by the outgoing flow of differentiated or apoptotic cells (see Figure 4.1). 
As a result, utilising Figure 4.1 and Figure 4.2, and based on the 
formulation in [20], the bone cell population dynamics can be formulated 
as follows: 
= D O B U \ K T P - NTFAMU I K P 2 • N P J L O B U ) - DOBP • OBP • NLFPOBP (4.5) 
^ = DOBP . OBP • NTRFPOBP - AOBA . OBA (4.6) 
^ - = TOBA-OBA-AOST-OST (4.7) 
= DOER • N M , 0 C P ~ " OCA • UTFCL OCA (4.8) 
where the subscript 'cell' in the input functions n m e a n s the cell 
type that a specific molecule binds to and 'molecule' denotes the ligand 
involved in a particular cell response. DOBU is the differentiation rate of 
uncommitted 
preosteoblasts, 
OB progenitors, DOBP is the differentiation rate of 
DOCI, is the differentiation rate of preosteoclasts, AOBA is the 
Figure 4.2: Schematic diagram of the mathematical model s tructure of mechanical loading causing 
bone remodelling at the cellular level 
rate of elimination of OBA, A(X.A is the rate of elimination of OCA and AOSR 
is the rate of elimination of OST. All the constants and their values can be 
found in Appendix B. 
Note that in this hierarchical model, there are two different time scales. A 
short time scale, which is less than 12 hours, is required to describe the 
production of NO and PGE2, and a longer time scale of several months (up 
to 12 months) is needed to capture the effects of these two factors and 
others on bone. 
Bone matrix is the largest source of TGF-P in the body [108]. TGF-P, 
growth factors and specific components embedded in the bone matrix are 
released by osteoclasts during bone resorption [109]. The effect of TGF-P 
on osteoblasts is bi-directional, depending upon the state of maturation of 
the osteoblasts [6], Conversely, TGF-p has the potential to stimulate 
osteoblast recruitment, migration and proliferation of osteoblast precursors 
(meaning OBPs in this model) [109]. However, TGF-P inhibits terminal 
osteoblastic differentiation into OB As [111]. In this model, it is assumed 
that the release rate of TGF-P from the bone matrix is constant, and the 
binding of TGF-P to its receptors is much faster than the changes in the 
number of OCA. Using the short time scale and a quasi-steady state 
assumption, the expression of TGF-P is [20]: 
Tfi= 'J- (4.9) 
Tp 
STp is a source/sink term for TGF-(3, a is the TGF-(3 content stored in bone 
matrix, Kres is the relative rate of bone resorption and Drp is the rate of 
degradation of TGF-(3. Consequently, the activation and repression forms 
of TGF-|3 can be obtained by substituting Equation (4.9) into Equations 
(4.2) and (4.3): 
nT/? m r p act,OBI] KDI.W+T/? (4.10) 
n s rep,OBP [+TJ3/K 
(4.11) 
D2,r/} 
n v -act,OCA KD3,Tp+^P 
(4.12) 
i J is the activation coefficient related to TGF-p binding on OBU, Km rp 
is the repression coefficient related to TGF-P binding on OBP and Km Tp is 
the activation coefficient of TGF-(3 binding on OCA. Applying the law of 
mass action [6] used to describe the reactions of receptors and 
corresponding ligands, the formulations including PTH with its receptor, 
RANKL with OPG and RANKL with RANK, can be found in the author's 
previous work [34]. 
In the model, PTH is used as a regulator of RANKL and OPG production. 
The assumption is that PTH endogenous production is constant, and 
PTHmm»PTH and PTH binding to its receptors on OBP and OB A is the 
same, to obtain PTH concentration and its according activation and 
repression functions as [20]: 
PTH = PPTH+PPTHM 
DPTH 
(4.13) 
UPTH 
1 1 act, OBP 
PTH 
KD.PTH+PTH 
(4.14) 
UPTH 
1 rep,OB A 1 + PTHj KD5PTH 
(4.15) 
where /3PTH is the synthesis rate of systemic PTH, Ppm d (/) represents an 
external PTH dosing term, Dpm is the rate of degradation of PTH, KD4 PTH 
is the activation coefficient for RANKLeff on OBP related to PTH binding 
and KD5 pth is the repression coefficient for OPG production related to PTH 
binding on OBA. This thesis has already argued that NO stimulates the 
production of OPG expressed in OBA (see Section 4.1.2) while PTH down-
regulates OPG production of OB A [34], Therefore, based on the work of 
[20] and using Equation (4.4), the OPG concentration can be expressed as: 
QPQ _ ' oba • (kPTH • Ylp™OBA + kNO • Tl"°OBA j + POPGd ( / ) 
~h ORA-ik •Upm +k .nwo ) ' POPG VD/t ^ PTH rep,OBA NO lVact,OBA) ft 
OPG +OPG max 
where pOPG is the production rate of OPG per OBA, kpm is the relative 
influence of PTH binding in production of OPG in OBA, kNO is the relative 
influence of NO in production of OPG in OBA, POPG d (t) is an external 
OPG administration term, DOPG is the rate of degradation of OPG and 
OPGmax is the maximum possible OPG concentration. In addition, NO 
inhibits RANKL expression in OBP and PTH up-regulates the RANKL 
'effective carrying capacity' of OBP [34]. Building on [20], the 
concentration of RANKL can be obtained: 
RL = 
RRL-OBP-UPZHOBP 
1 + KMM-OPG + KA,RL-RK 
P r L • Q B P • ^ Z,OBP + Pl<L,d (Q 
+DRL.RRL.OBP. n^Bp 
(4.17) 
B OBPYINO 
s HRL yJL>r 1 1 rep JOBP 
RRL is the maximum RANKL on OBP, KM RL is the association binding 
constant RANKL-OPG, KA2 RL is the association binding constant RANKL-
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RANK, pRI is the production rate of RANKL per OBP, PRLJ{t) is an 
external RANKL administration term and Dm is the rate of degradation of 
RANKL. Then the activation function of RANKL on differentiation of 
osteoclast precursor cells OCP can be obtained using Equations (4.2) and 
(4.17): 
(4.18) 
D6.RL + K L 
KD6 rl is the activation coefficient related to RANKL binding on OCP. 
Now the unknown parameters are nN°ORA, Tl™OBP and Ylacl OBU 
Y\no H — (4 19) act tOBA M \ r - L y J 
KDI,NO+NO 
V H — (4-2°) 
1 + N O / K D ^ N O 
n a c t f l B U ~ „ j. P9 (4.21) 
which directly relate to the concentrations of NO and PGE2 caused by 
mechanical loading. Here, 
NO the activation coefficient for OPG 
production on OBA related to NO, KDiNO is the repression coefficient for 
RANKL production on OBP related to NO and KD9P2 is the activation 
coefficient for OBU differentiation related to PGE2. 
Here, a loading regime is defined, which is also widely used in animal tests 
[38, 122]. The number of loading cycles during a training day is N, Tres, (h) 
is the rest time between loading bouts and n is the number of loading bouts 
per day. The amplitude (A [Pa]) and frequency ( / [Hz]) of the interstitial 
fluid shear stress (IFSS) caused by the loading can be measured using the 
method in [123]. Therefore, the peak fluid shear stress rate RIFSS (Pa-Hz) 
can be defined as [45]: 
R,FSS=2n-A-f (4.22) 
The interstitial fluid flow is only formulated in terms of load, as can be 
observed in Equation (4.22), which means that being an intermediate 
variable it is not actually modelled. However, it is still worth stating the 
interstitial flow being the physical mediator of mechanotransduction by 
osteocytes. This completes the crucial transduction from mechanical 
stimuli to biochemical signals, which is concluded for the first time in the 
field after an extended literature review. This conclusion will help other 
researchers in the field understand the mechanism of mechanotransduction 
of bone remodelling under mechanical stimulus and propose other possible 
models in the future. 
To study the sensitivity of bone remodelling to mechanical loading, the 
mechanosensitivity of osteocytes ( MSOST ) is defined with the frequency ( / ) , 
number of loads per day (N), the rest time between bouts (Tresl) and the 
length of loading period (/). The experimental results indicate that loading 
will not have an effect on bone formation if its frequency is less than 0.5 
Hz [124], and the sensitivity of bone changes little when the loading 
frequency becomes greater than 10 Hz [125]. However, [126] demonstrated 
that loading at frequencies up to 90Hz can still have an effect on bone 
formation. A logarithmic function is used to describe the relationship 
between frequency ( / ) and osteocyte mechanosensitivity (MSOSR): 
Data from [2] show that osteocyte sensitivity to mechanical loading is 
proportional to l / (N+l): 
MSOST ocln(/ + 0.5), MSOST > 0 (4.23) 
MSOST OC 7V + 1 (4.24) 
which means that bone loses more than 95% of its mechanosensitivity after 
only 20 loading cycles. It can be imagined that osteocytes will regain their 
sensitivity after a period of rest between loading bouts. Data from [127] 
demonstrated the following relationship: 
where r is a time constant approximately equal to 6h [127]. It is noted that 
98% of bone mechanosensitivity is regained after 24h of rest. 
Bone cells accommodate to routine loading, which means that bone 
mechanosensitivity drops as the loading period extends. Here, it is 
hypothesised that bone mechanosensitivity follows the relationship with 
loading period t (days): 
where Tacc is the time constant describing the rate at which accommodation 
takes place, here assumed to be 24 days [128]. Making use of Equations 
(4.23) to (4.26), the osteocyte mechanosensitivity can be written as: 
MSOST oc(2-e-^) (4.25) 
MSnvr oc e-'/T° OST (4.26) 
ln(/ + 0.5) , T , „ T MSosr=KMS> . + i (4.27) 
where is a proportionality constant. 
In most animal experiments, the mechanical stimulation is applied no more 
than one hour per day and lasts for several months [38, 122]. The 
conclusions from animal studies are that limited benefit is derived from 
additional loading cycles above approximately 40 cycles per day [23], and 
it has been clear that NO and PGE2 production appears within minutes [47] 
when the mechanical loading starts and finishes several hours after the 
loading stops [129]. In this chapter, the short time scale is used to describe 
NO and PGE2 production caused by mechanical stimulus, which is 
assumed to be much faster than changes in the number of osteocytes (long 
time scale) in remodelling BMUs. Using Equations (4.22) and (4.27), and 
based on the experimental results [44, 45], the concentration changes of 
NO and PGE2 during bone remodelling process are defined as: 
dNO KNO • Rifss •OST n[ MSostdN -Dm • NO (4.28) 
dt 
dP2 
KPI ' RIFSS 'OST •n f MSOSTdN - DP2 • P2 (4.29) dt 
Km is the secretion rate of NO by osteocytes, n is the number of loading 
bouts per day, KP2 is the secretion rate of PGE2 by osteocytes, DNO is the 
rate of degradation of NO and DP2 is the rate of degradation of T PGE2. 
There are now six unknown variables, OBP, OBA, OST, OCA, NO and P2, 
and six independent equations (4.5), (4.6), (4.7), (4.8), (4.28) and (4.29). 
Using Matlab, this ODE system can be solved and the numerical results for 
each variable can be obtained. 
Then, following the method used in the author's previous work [34], it is 
assumed that bone formation and resorption rates are proportional to the 
number of active bone cells, that is: 
^ 1 L Kfor • [OBA(t) - OBA(0)] - Kres • [OCA(t)-OCA(0)] (4.30) 
Note that BMC is the bone mineral content (BMC) in percentage (%) and 
Kfor and Kres are the relative bone formation and resorption rates. The 
simulation starts from a so-called 'steady-state' in which the values of 
model variables keep constants as initial values such as BMC{t) = 100%, 
OBA(t) = OBA(0) and OCA{t) = OCA(0). Therefore, model Equations (4.5) to 
(4.8) become (4.31) to (4.34) respectively: 
0 = D O M , • NRAPAOBU - DOBP • OBP (0) • NLFPOBP (4.31) 
o | D O B P - O B P ( 0 ) - T 1 % O B P - A O B A OBA(0) (4.32) 
0 = TOBA • OBA (0) - A^ • OST(0) (4.33) 
0 = D(X:P • N%LOCP - AOCA . OCA(0) • NFJL OCA (4.34) 
By solving Equations (4.31) to (4.34) the initial values of the model 
variables in Table 4.1 can be obtained. 
Table 4.1: Initial values of the model variables 
Symbol Unit Value 
OBA(O) pM 0.2126991130e-3 
OBP(O) pM 0.8986869185e-5 
OCA(O) pM 0.2769166993e-3 
OST(O) pM 0.1029189256e-2 
The mechanical stimulus is able not only to increase bone mass but also to 
improve bone strength by influencing collagen alignment as new bone is 
being formed by osteoblasts during bone turnover. Cortical bone tissue 
located in regions subject to predominantly tensile stresses has a higher 
percentage of collagen fibres aligned along the bone long axis [23]. In 
regions of predominantly compressive stresses, collagen fibres are more 
likely to be aligned transverse to the long axis [130]. Evidently, this 
arrangement functionally improves bone tensile properties with more 
collagen fibres oriented in the longitudinal direction [131], whereas bone 
compressive properties are improved by transversely oriented collagens 
[132]. 
In an experiment by Robling et al. [38], cyclic mechanical loads were 
applied axially along the ulna of adult rats for 16 weeks. The results 
indicated that the pattern of bone formation caused by loading resembled 
the stress distribution, with more bone formation where the stresses were 
highest. Robling et al. tested the mechanical properties and BMC of the 
sample before and immediately after the experiment stopped. They 
compared and analysed the data (before and after the experiment) and 
found that the bone structure had improved, with a 69% increase in the 
second moment of area. Bone strength increased by 64% and the energy 
absorbed before fracture (BFE), which is of more practical interest to 
clinical practice, increased by 94%, while the BMC improved by only 7%. 
The results demonstrate that BMC is only one of the factors that 
contributes to bone strength and it is the BFE that is able to evaluate the 
effect of mechanical bone remodelling comprehensively. Consequently, 
using BMC to characterise bone remodelling, which has been used in the 
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existing mathematical models [6, 20], is not suitable to measure the effect 
of bone remodelling under mechanical stimulus and is therefore replaced 
by BFE in this model. 
In this chapter, the BFE that the energy absorbed before fracture is used as 
a more appropriate standard to assess the significance of bone remodelling 
under mechanical stimulus. The BFE can be measured through 
experimentation; here, using the cell population dynamics model, it is 
proposed that the formulation of calculating BFE is: 
+ Klo-yjOBA(t) + OCA(t) 
where Kto is the relative rate of bone turnover. By substituting Equation 
(4.30) into Equation (4.35), it can be observed that BMC contributes to 
BFE: 
(4.36) 
It is proposed in the paper that BMC linearly contributes to BFE, which is 
the first term in Equation (4.36). The second term in Equation (4.36) 
represents the contribution of bone turnover (OBA(t) + OCA(t)) to BFE in 
order to consider the structural effects of optimised collagen alignment to 
bone strength in newly formed bone. It is observed in the experiment [23, 
130-132] that the contribution of bone turnover to the increment of bone 
strength diminishes as bone turnover increases. This thesis postulates that 
the square root of bone turnover contributes to the derivative of BFE to 
time. By applying the superposition principle, the relationship of BFE with 
BMC and bone turnover can be obtained in the form of Equation (4.36). 
The validity of the proposed equations will be tested in the following 
section. This equation might not be completely accurate but it fits the 
model well, which at least provides an alternative understanding as to the 
relationship between BFE, BMC and bone turnover. 
In this chapter, all the parameter values used in the model are from 
experiments, and are not varied or modified to fit the experimental data. A 
cursory examination of the parameters indicates two classes. The first class 
corresponds to the physico-chemical parameters: KD] rp , KD2T0 , Km Tp , 
K-DH,PTH » KD5 PTH , Kd6 RL , KD7 NO , Km m , KD9 P2, Tacc, KM R] , KA2 RL , kNO , kPTH , 
KP2 ? KTP , PPTH > PM 5 POPG ' DPM , DI{L , DOPG , DJP , ML , DP2 and r . These 
parameters generally remain fixed under different physiological conditions, 
are easily measured through experiments and have values reported in the 
literature. The second class of parameter value may fluctuate slightly if the 
larger physiological environment changes, these are: AOBA, DOBU, DOBP , T0HA, 
1 DOCP, A(X.A , KNO , KP2 , KFOR, KRES, KLO, RK, a , OPGMSX a n d RLIL . T h e 
values for these parameters are averaged from a range of acceptable values 
for each parameter by checking the literature. In this paper, most parameter 
values are referred from previous models in the field [6, 20], the new 
parameter values are from [66, 67, 127, 128] (see details in Appendix B). 
4.3 Numerical Investigation 
Mathematical models of biology are a form of complex hypothesis. To test 
the validity of the hypothesis, external data is utilised, which has never 
been used in the creation of the model, to see if the model matches the 
experiments. Ideally, the model should be tested by as many experiments as 
possible to see if it is valid in a statistical sense. However, the reality is that 
due to the complexity of such experiments and suitability of the specific 
model, there are not many experiments available for comparison. This 
paper simulates five experiments of two different types in [122] and [38]. 
The future work will be to test the model using more experiments when 
available. 
First, this study simulates the three experiments conducted in [122], in 
which 57 female Sprague-Dawley rats were randomised to three groups: 
group I, loading was applied for five weeks followed by ten weeks of time 
off (1x5); group II, loading was applied for five weeks followed by five 
weeks of time off and loading again for five weeks (2x5); and group III, 
loading was applied continuously for 15 weeks (3x5). An axial load was 
applied to the right ulna for 360 cycles per day, at 2 Hz, three days per 
week at 15 N. This study simulates the effects of three different loading 
schemes on BMC and compares them with the experimental results, which 
are shown in Figure 4.3. 
a 
Time [days] 
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Figure 4.3 Simulation results of experiment in |122|. a: BMC (percentage) dynamics during the 
experiment period, 15 weeks for loading scheme 1x5 and 3x5. b: BMC (percentage) dynamics 
during the experiment period 15 weeks for 2x5 loading scheme, c: Trend comparison of experiment 
and simulation results. In Figures 3a and 3b, the small squares and circles with the words 
'Experiment 1501' and 'Present model' represent the experimental and current simulation results 
respectively on the 105th day 
The trends of BMC of loading schemes 1 x 5 and 3x5 are shown in Figure 
4.3a. From the dot curve, it can be observed that for the 1x5 loading 
scheme, the BMC retains its initial value for the first four to five days of 
loading, which is in agreement with bone remodelling theory. It then begins 
to increase almost linearly under the mechanical stimulus until the loading 
stops on the 35th day. Next, due to the accumulated NO and PGE2, the 
BMC continues to increase but the bone formation rate (the gradient of 
curve) drops until BMC reaches its peak value when bone formation rate 
becomes zero on approximately the 50th day. The bone remodelling then 
maintains its new equilibrium and the BMC remains unchanged. 
During the 3x5 loading scheme, the BMC follows the same pattern as the 
1x5 scheme for the first five weeks. The mechanical stimulus continues for 
another ten weeks, when the bone formation rate decreases slowly towards 
the end of the experiment (15 week loading). By the end of the experiment, 
each rat's BMC was measured and compared with its BMC before the 
experiment. The measured BMC increases (in percentage) are shown in the 
graph by the small circles and squares with the word 'Experiment [122]'. 
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They are 7.6% and 10.4% for the 1x5 and 3x5 schemes respectively. The 
simulation results are shown by the small circles and squares with the word 
'Present model', predicting 6.1% and 9.1% increases for the 1x5 and 3x5 
schemes respectively. 
The pattern of BMC with respect to time (days) for the 2x5 loading 
scheme is plotted in Figure 4.3b. From day 0 to day 70 (five-week loading 
plus five-week rest), the BMC demonstrates exactly the same pattern as 
that in the 1x5 scheme, as expected. After a five-weeks break, the bone 
cells regain some mechanosensitivity and start to respond to the mechanical 
loading from day 71 as predicted. However, the graph shows clearly that 
the bone formation rate is less than that in the first five weeks, which 
implies that the bone mechanosensitivity has not fully recovered after five 
weeks of rest. Eventually, the experiment shows a 9.8% increase and the 
simulation predicts an 8.4% increase (see the small squares with the words 
'Experiment [122]' and 'Present model', representing experimental and 
current simulation results). 
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Figure 4.4: Simulation results and comparison with those from the experiment in [38|. a: BMC 
(percentage) dynamics during the extended loading period of 170 days, b: energy (percentage) 
absorbed before bone fracture dynamics during the extended loading period of 365 days, c: bone 
turnover (OBA+OCA) dynamics, d: OCA/OBA during the loading period, e: OB A, OCA, OBP cell 
population dynamics during the loading period (360 x 1). f: messengers NO and PGE2 population 
dynamics during the loading period (360 x 1). Note that in Figures 4a and 4b, the small squares and 
circles with the words 'Experiment |8)' and 'Present model' represent the experimental and 
current simulation results respectively on the 112th day. 
In Figure 4.3c, the three experimental results from [122] are plotted and 
connected with solid line segments, while the corresponding three 
simulation results are plotted and linked with dash line segments. In a 
model of this complexity, a close match of quantitative data is mostly based 
on the careful choice of parameters. However, what is more important is 
the ability of the model to predict the qualitative pattern of the response. As 
can be seen from the graph, the trend of simulation is inconsistent with the 
experiments. For the same reason, the focus in the following comparisons 
will be on the trends of changes (percentage of increase or decrease) rather 
than the values themselves. In this particular experiment, one clear 
conclusion is that inserting the rest period into the exercise regime does not 
result in a proportional decrease in bone gain. On the contrary, the bone 
gain in the 2x5 and 3x5 loading scheme is similar: 8.4% versus 9.1% 
(only 8.3% difference) in the simulation and 9.8% versus 10.4% (only 
6.1% difference) in the experiment. It is much higher than the 1x5 loading 
scheme, which is 6.1% in the simulation and 7.6% in the experiment. 
In another two experiments from [38], the right ulnas of 26 adult female 
rats were subjected to 360 load cycles/day, delivered in a haversine 
waveform at 17 N peak force, 2 Hz, three days per week for 16 weeks. Half 
of the rats (13) were administered all 360 daily cycles in a single 
uninterrupted bout (360x1); the other half were administered 90 cycles four 
times per day (90x4), with 3h rest time between bouts. At the end of 
intervention, the BMC and BFE were measured for each rat, and 
statistically analysed and compared with the non-loaded baseline control 
group. The simulation and experimental results are demonstrated in Figure 
4.4. 
Figure 4.4a shows the BMC dynamics during an extended loading period 
(more than 16 weeks) for the 360x1 and 90x4 loading schemes. BMC 
remains almost its initial value in the first week, which agrees with the 
bone remodelling cycle theory. The bone formation rate and BMC value 
for loading scheme 90x4 then become greater than the 360x1 loading 
scheme, which agrees with the experimental observation [38]. The bone 
formation rate in both cases diminishes as time elapses as can be observed 
from the graph. The study continues to draw the graph (which means the 
loading continues in the experiment) and it is interesting to note that it 
takes less time for BMC to achieve peak value in the 90x4 loading scheme 
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(150 days) than the 360x1 loading scheme (180 days). Unfortunately, there 
is no such experiment to verify this finding. 
By the end of the experiment (16 weeks loading), the simulation shows a 
5.5% and 8.8% increase of BMC for the 360x1 and 90x4 loading schemes 
respectively (see the small circles and squares with the words 'Present 
model' on the solid and dot curves), while the measured changes in 
experiments are 6.9% and 11.7% respectively [38] (see the small circles 
and squares with words 'Experiment [38]'). Again, the significance of the 
model is the ability to predict the trend of the increase percentage of BMC, 
which is 60% in simulation (from 5.5% to 8.8%) and compares well with 
the 69.6% (from 6.9% to 11.7%) in the experiment. The conclusion is 
significant to mechanical stimulus therapies because separating loading 
into short bouts such as 90x4 in this experiment not only achieves greater 
BMC but also uses less time compared with one long loading bout such as 
360x1 in this case. 
Using the newly proposed standard, the dynamics of the BFE in the 
extended loading period (365 days) are calculated in Figure 4.4b. The 
results show that the BFE increases in an almost linear way with respect to 
time (days) until approximately the 150th day in the 90x4 loading scheme 
and the 180th day in 360x1 loading scheme, which matches the timing when 
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BMC peaks in Figure 4.4a. The BFE then continues to grow linearly at a 
smaller rate, probably because the BMC stops increasing in both cases. The 
distinguishing difference between Figure 4.4a and Figure 4.4b is that the 
BFE continues to grow even after BMC stops increasing, which means that 
bone strength continues to benefit from mechanical stimulus although bone 
mass hardly gains. The simulation results indicate a 72.8% and 131.6% 
increase of BFE for 360x1 and 90x4 loading schemes respectively after a 
16 week loading period (see the small circles and squares with words 
'Present model' on the solid and dot curves). The measured changes in the 
experiment are 94% and 165% respectively [38] (see the small circles and 
squares with words 'Experiment [38]'). Once again the quantitative value 
itself of each increase in the loading schemes 360x1 and 90x4 is not the 
focus, what is more important is the trend of increase percentage, which is 
80.8% (from 72.8% to 131.6% ) in simulation. This compares well with 
75.5% (from 94% to 165%) in experiments. 
Comparing the increase of BMC in Figure 4.4a and BFE in Figure 4.4b, the 
present study shows that these small gains in BMC (from 5.5% to 8.8%) 
impart very large increases in BFE (from 72% to 131%) because the new 
bone formation is localised to the most mechanically needed sites. 
Consequently, it is possible to enhance fracture resistance significantly 
through mechanical loading such as exercises. Most exercise intervention 
studies yield increases in BMC of only a few per cent at most. This might 
be a significant difference between pharmacologically-induced bone 
formation and loading-induced bone formation. For example, intermittent 
administration of PTH adds new bone mainly to the endocortical and 
trabecular surfaces, which makes relatively little contribution to resist 
bending [133]. Therefore, mechanical loading appears to be able to not 
only increase bone mass but also more importantly, spatially optimise the 
new bone formation to obtain maximal bone strength. 
The dynamics of bone turnover (OB A+OC A) during the loading period for 
360x1 and 90x4 loading schemes can be observed in Figure 4.4c. From the 
beginning to approximately the 30l day, both loading schemes cause bone 
turnover to increase quickly at a similar rate (with the value of 90x4 
slightly greater than that of 360x1). Next, it is surprising that the bone 
turnover of 90x4 drops faster than the 360x1 loading scheme, which 
implies less bone cell activity in samples from the 90x4 loading scheme 
after bone cells become desensitised from the 30th day. 
Figure 4.4d presents the ratio OCA/OBA dynamics in the loading period 
for 360x1 and 90x4 loading schemes, starting f rom OCA/OBA«1.25 in 
healthy adults, which is consistent with [6]. Both ratios show almost the 
same pattern and value: they drop quickly since the mechanical loading 
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applies, from 1.25 to about 0.1 on the 20th day, and then remain almost 
unchanged until the end of experiment, which predicts an osteogenic 
outcome after loading. 
Using the model from this study, besides BMC, which can be measured 
easily through experimentation, insight can also be gained into the cellular 
dynamics of OBA, OCA and OBP during the loading period, which is 
difficult or perhaps impossible to measure during the experiment. Figure 
4.4e shows the population dynamics of OBA, OCA and OBP during the 
360x1 loading period. It can be observed that OBA reacts quickly to the 
mechanical loading with a large increase rate because of the positive effect 
of PGE2 in the first 30 days. It then continues to drop slowly to the end of 
experiment, which is consistent with the decrease of PGE2 in Figure 4.4f. 
Due to the inhibitory effect of NO on OCA through the 
RANK/RANKL/OPG pathway, the number of OCA drops slightly because 
of limited production and degradation. Under the stimulatory effect of 
TGF-p (limited because of the limited activity of OCA) and PGE2, the OBP 
number increases slightly compared with the initial value and reaches 
almost the same value as OCA from day 60. 
Figure 4.4f depicts the population dynamics of NO and PGE2 in the 360x1 
loading period. NO responds to the mechanical stimulus quickly, with a 
rapid increase in number at a high rate. PGE2 is also found to increase, 
which is consistent with the experimental results (see Section 4.2.1). Both 
numbers of NO and PGE2 start to decrease from the 30l day, probably 
because the bone cells accommodate the routine loading and become 
desensitised. 
4.4 Summary 
The proposed model is developed based on the following assumptions and 
limitations: 
• The bone remodelling initiated by mechanical loading starts by 
programmed cell death in osteocytes [134]. It is still not known what 
factors cause osteocyte death. In the model, the osteocyte death at the 
beginning of bone remodelling is not taken into account. 
• The amounts of uncommitted osteoblastic progenitors (OBU) and 
OCP are assumed very large, for which reason the numbers of OBU 
and OCP do not appear in the model. 
• In the numerical simulations, the RANK concentration is fixed and 
this assumption could be relaxed in a future study. 
• PTH endogenous production is considered as constant and not 
further regulated. 
• The model is based on the so-called 'convergence hypothesis' that 
all the activities of resorptive or anti-resorptive agents converge at 
the level of RANKL and OPG through which the final effects are 
achieved. 
• The change in bone shape, namely the macroscopic bone surface 
remodelling, is not included here, which explains why there is no 
spatial distribution in the current model. 
In this chapter, a bone cell population dynamics model was proposed for 
cortical bone remodelling under mechanical stimulus. A few features of 
this model are proposed for the first time in this field: 
• The osteocyte is proposed as the physical mediator of 
mechanotransduction in bone remodelling under mechanical 
stimulus and its population is introduced into the mathematical 
model; 
• Three new rate equations describing changes of osteocytes, nitric 
oxide (NO) and prostaglandin E2 (PGE2) are incorporated into this 
model; 
• The effect of loading frequency on bone mechanosensitivity is 
investigated; 
• The influence of the number of loading cycles during a loading day 
and the recovery of bone mechanosensitivity between two loading 
bouts as well as during the whole loading period are explored; 
• The Hill equation is extended to two ligands binding to the same cell; 
and 
• The good agreement between the simulations and the experimental 
results is very encouraging, and indicates the correct understanding 
of the mechanical bone remodelling at the cellular level. 
Chapter 5: Parametric Study of Control Mechanism of Bone 
Remodelling under Mechanical Stimulus 
From a perspective of control mechanism, it is believed that there are 
several control mechanisms working simultaneously in bone remodelling, 
which is a complex process. In this chapter, an extensive parametric study 
is conducted to investigate model parameter space related to cell 
differentiation and apoptosis, which can describe the fundamental cell 
lineage behaviours. After analysing all the combinations of 728 
permutations in six model parameters, a small number of parameter 
combinations have been identified that can lead to physiologically realistic 
responses, which are similar to theoretically idealised physiological 
responses. 
5.1 Mathematical Model Development 
Following the same method used in the author's previous work, this study 
uses the abbreviated forms for the concentration (unit: pM) of factors 
involved, including: OBU for uncommitted osteoblastic progenitors; OBP 
for preosteoblast; OBA for mature osteoblast; OCP for osteoclast precursor; 
OCA for active osteoclasts; OST for osteocytes; RL for RANKL; RK for 
RANK; Tp for TGF-p; and P2 for PGE2. OPG, NO and PTH remain 
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unchanged. In the following section, the model developed in Chapter 4 is 
briefly recalled. 
In modelling cell responses, the Hill equation is often used to describe the 
molecular input function. The activation (act) and repression (rep) forms of 
the Hill equation [121] for the production rate of a new cell or molecule are 
[20]: 
f ^ h P - ^ - ^ - r (5-2) 
1 + — 
K2 
where x* is the active form of concentration, x is a ligand that governs the 
production of a cell or molecule ( z ) through binding to its receptor on cell, 
(5 is the maximal production rate of z, and Kx and K2 are activation and 
repression coefficients. It has already been assumed that the Hill coefficient 
equals one. 
The equations governing the evolution of the number of osteoblastic and 
osteoclastic cells in each maturation stage are simply balance equations, 
which means each cell stage is fed by an entering flow and is emptied by 
the outgoing flow of differentiated or apoptotic cells. As a result, the 
mechanical bone cell population dynamics can be formulated as follows: 
dOBP 
dt DQBU '\Kp ' nactflBU
 + kp2 ' ^ acl,OBU ) ^OBP ' OBP • IlJpOBP (5.3) 
dOBA 
dt 
= DOBP-OBP-UT^OBP-AOBA-OBA (5.4) 
dOST 
dt = TnR. • OBA - A,kt • OST OBA VST 
(5.5) 
, ^OCP act,OCP -A, OCA •OCA-URFCLOCA (5.6) 
the input functions are derived using the Hill equations, whereby 
'cell' means the cell type a specific molecule binds to, 'molecule' denotes 
the ligand involved in a particular cell response and 'rep/act' means 
repressor or activator function. For example, TfJl OBU, nTr^ pOBP and nTJl OCA 
are the activator/repressor functions related to TGF-P binding to its 
receptors on osteoclasts and osteoblasts. DOBU is the differentiation rate of 
uncommitted OB progenitors, DOBP is the differentiation rate of 
preosteoblasts, DOCP is the differentiation rate of preosteoclasts, AOBA is the 
rate of elimination of OBA, A ^ is the rate of elimination of OCA and AOSR 
is the rate of elimination of OST. All the model parameters and their values 
can be found in Appendix B. 
Here, a loading regime is defined, which is also widely used in animal tests 
[3, 4], The number of loading cycles during a training day is N , TRESL (H) is 
the rest time between loading bouts and n is the number of loading bouts 
per day. The amplitude (A [Pa]) and frequency ( / [Hz]) of the interstitial 
fluid shear stress ( I F S S ) caused by the loading can be measured using the 
method in [123]. Therefore, the peak fluid shear stress rate RIFSS (Pa-Hz) 
can be defined as [45]: 
To study the sensitivity of bone remodelling to mechanical loading, the 
mechanosensitivity of osteocytes ( M S O S T ) is defined with the frequency ( / ) , 
number of loads per day (N), the rest time between bouts (Trest), the length 
of loading period ( t ) and the time constant describing the rate at which 
accommodation takes place (TACC). The osteocyte mechanosensitivity can be 
written as: 
RIFSS=2nAf (5.7) 
mm = m. • • B ^ J b f t l f c . (5.8) N + \ V 
where Km is a proportionality constant. 
Using Equations (5.7) and (5.8), and based on the experimental results [44, 
45], the concentration changes of NO and PGE2 during the bone 
remodelling process can be defined as: 
Rifss OST-n f MSOSTdN-DNO-NO (5.9) at 
— = KP2 • Rifss • OST • n f MSOSTdN - DP2 -P2 (5.10) 
dt * 
KNO is the secretion rate of NO by osteocytes, n is the number of loading 
bouts per day, KP2 is the secretion rate of PGE2 by osteocytes, DNO is the 
rate of degradation of NO and DP2 is the rate of degradation of T PGE2. 
In the end, this study defines the system output as the BMC and BFE: 
= Kfor • [OBA(/)-OBA(0)]-Kres .[OCA(t)~OCA(0)] (5.11) 
j d p r 
^ = Kfor.[OBA(t)-OBA(0)]-Kres{OCA(t)-OCA(0)] | ^ 
+ Klo-JOBA(t) + OCA(t) 
Note that BMC and BFE are in percentage (%), Kfor, Kres and Klo are the 
relative bone formation rate, bone resorption rate and the relative rate of 
bone turnover respectively. This study starts the simulation from a so-
called 'steady-state' in which BMC and BFE are 100%, dBMC/dt = 0 , 
dBFE/dt = 0, correspondingly OBA(t) is OBA(0) and OCA(t) is OCA(0). 
5.2 Parametric Study of the Control Mechanism 
In normal adults, there is a balance between the amount of bone resorbed 
by osteoclasts and the amount of bone formed by osteoblasts [23]. In this 
complex process, bone is remodelled by groups of cells derived from 
different sources, usually called the BMUs [24], that follow an activation-
resorption-formation sequence event. The BMU is a mediator mechanism, 
bridging individual cellular activity to whole bone morphology [81], which 
is sensitive to any changes in the bone cell microenvironment. As a result, 
it is expected that any modification to the component of BMU will have a 
significant effect on its output behaviour. 
In this paper, perturbations will be applied to the mechanical bone 
remodelling system that is in a steady state, by down- and up-regulating its 
six differentiation and apoptosis rate parameters DFobu, DFocp, DFobp, Aoba, 
Aoca and Aosl . In this case, there are six different parameters and each 
parameter could be either up- or down-regulated. Using a simple 
combination theory, the number of permutation is calculated 
as 728 = Y q -2'. Next, in order to investigate the system behaviour for a 
i=1 
wide range of changes, the exponentially changed factor is now applied 
(1.5ex) to each of the six differentiation and apoptosis rate parameters, 
whereby the exponent ex ranges from -10 to 10 in step increases of 0.5. The 
assessment of each of the parameter combinations to the system behaviour 
is chosen as the responses of BMC and BFE, which are sampled on 100l 
day to stand for the maximum change. Using Matlab (see the Matlab code 
in Appendix D.l), all of the 728 graphs can be plotted. Then, by 
summarising all of the plots of BMC and BFE versus variation of exponent 
ex, it is found that there are three subsets of curves, which are plotted in 
Figure 5.1. 
Figure 5.1a and Figure 5.1b show an exponential increase and decrease of 
BMC and BFE respectively, for increasing the model parameter 
exponentially (exponent ex from -10 to 10). This type of behaviour is 
considered as physiologically unrealistic from a biological perspective and 
is obtained for quite a large range of model parameter combinations. 
Conversely, Figure 5.1c represents the other extreme, whereby only minor 
changes of BMC and BFE occur during the entire range of parameter 
variation. These three types of response curves are excluded from further 
analysis because they do not provide an effective control mechanism for 
BMC and BFE. 
In [20], the 'idealised' regulatory response by functionally active BMUs is 
discussed. As was stated earlier, the bone remodelling system starts from a 
steady state in which it can be identified that ABMC = 0 , A BFE = 0 , and 
concentrations of various hormones, growth factors that cause initial values 
of differentiation and apoptosis rates in BMUs. In order to respond to 
minor changes in concentrations, it is expected that BMUs should be rather 
insensitive to these fluctuations. Therefore, from Figure 5.2, it can be 
recognised that point A is the threshold concentration, which means any 
change of model parameter underneath A causes no change in BMC (/BFE). 
In addition, a region around the usual operation status of BMUs should be 
found with relatively small gradients of changes in BMC (/BFE) in 
response to changes in differentiation rates (regions C-D and D-E in 
Figure 5.2), with larger gradients for larger changes in differentiation rates 
(region E-F in Figure 5.2). It is expected that this response in BMC (/BFE) 
change will remain limited if the differentiation rates increase significantly 
(region further after point F in Figure 5.2) because the unlimited rise of 
BMC (/BFE) is not physiologically realistic. Conversely, it is expected that 
the rate of BMC (/BFE) change would also decrease in a limited manner if 
the differentiation rates decrease significantly. In fact, physiologically, it is 
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reasonable for the BMC (/BFE) change to be zero for extremely small 
differentiation rates. Additionally, it can be observed from Figure 5.2 that 
point F marks the maximum change in BMC (/BFE) (AB max). Since there 
is no point A, which is the maximum concentration that does not lead to 
further modifications of BMC (/BFE), there must be a transition region 
from point C to A that is characterised by point B, the lowest value of 
BMC (/BFE). 
Having found a potential 'ideal response curve', a search for response 
curves that may meet these requirements can begin. Encouragingly, this 
research has been able to identify a small number of curves that possess 
similarity to the idealised response curve. Table 5.1 summarises all the 
parameter combinations that produce idealised response curves. Figure 5.3, 
illustrates the physiologically realistic response curve, which corresponds 
to the parameter permutation involving three parameters (AOBA,AOCA,AOSJ.=-
1+1+) and is similar to the idealised response curve shown in Figure 5.2. 
It is noticed that in a bone remodelling system without consideration of 
mechanical stimulus, the response involving three parameters 
( DOBU / DOBP / A(X,A =+/-/+) coincides with the known physiological action of 
TGF-(3 on bone cells. TGF-p promotes differentiation of osteoblast 
progenitors and inhibits differentiation of osteoblast precursor cells, while 
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promoting osteoclast apoptosis [20]. However, in the case of mechanical 
bone remodelling, this combination causes exponential increases for both 
BMC and BFE, which is similar to that which is illustrated in Figure 5.1a. 
In other words, with the introduction of mechanical stimuli, the bone 
remodelling system changes and this deserves attention from biologists and 
other researchers. 
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Figure 5.1: Physiological unrealistic changes of BMC and BFE versus combined changes of model 
parameter |1 .5"1 0- 1.5+1°l/»: (a) exponential bone growth, (b) exponential bone decrease, (c) slight 
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Figure 5.2: Schematic illustration of ideal response curve for combined changes of model 
parameters (Modified from Pivonka et al. |20|) 
Table 5.1: Summary of parameter combinations that lead to controlled remodelling processes. The 
variation with '+ ' represents parameter i n c r e a s e , r e p r e s e n t s parameter decrease 
Number of 
parameters in a 
combination 
Combinations of differentiation 
and apoptosis rates 
Variation of 
each parameter 
1 A OBA — 
1 A>ST — 
2 N I A 
OBP OBA + / -
2 N / A OBP NOST 
2 N 1 A ^OCP' OBA - / -
2 D / /f ^OCP' OST - / -
2 A 1 A OBA ' OCA - / + 
2 A 1A nOCA ' OST +/-
3 DOBP ' DQCP / AQBA 
3 DOBP ' DQCP / A)BA 
3 n / A / A OBP ' OBA ' ^OCA 
3 D 1 A / A OBP ' OBA ' OCA - 1 - 1 + 
3 n / A / A OBP ' OBA ' ^X)ST 
3 n / a / A OBP ' OBA ' OST +1-1+ 
3 A / A / A OBA ' OCA ' OST -1+1+ 
4 D0BU ' DOBP / Aoba ! A)ST +/+/+/-
4 D()BP ' DqcP ' AOBA ! AOCA 
4 DOBP ' DQCP ! Aoba / A(X:A 
4 ™OBU ' Docp ' AOBA / Aosr 
4 DOBP ' AOBA / A x A ! A)ST 
4 OBP ' A)BA ! ^OCA ! AjST 
5 OBU ' DQBP ! Dqcp / A()ba / Aosr 
5 BOBU ! Dobp / A x / > ^ A)BA ! AOST 
5 DOBU ' Dobp / Aoba / Aoca / A o s t 
5 OBU ' Dobp ! Aoba / Aoca / Aosr 
5 D / D / A / A 1 A ^OBP ' OCP f OBA | TOfp! OST 
5 D I B 1 A 1 A / A OBP ' ^OCP ' -"-OBA ' jPEpi OST 
5 D / D 1A 1 A 1 A OBP ' SpOCP ' OBA ' ^(X'A 1 OST 
6 ^OBII ' DQBP / / Aoba / Aoca / Aost 
6 DQBU ' Dobp / Dqcp / Aoba / A(X A / Aost 
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Figure 5.3 Typical physiologically-realistic fluctuations of B M C and BFE with combinations of 
parameter change 
5.3 Summary 
In this chapter, based on the work in Chapter 4, the parametric study of 
mechanical bone remodelling model was conducted in order to understand 
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the control mechanism of mechanical bone remodelling at the cellular level. 
Consequently, this study can perform an extensive parametric study 
investigating model parameter space related to cell differentiation and 
apoptosis, which describes the fundamental cell lineage behaviours, to 
investigate such a scenario. After analysing all the combinations (728 
permutations) of six model parameters, this study successfully identified a 
small number of parameter combinations that are able to cause 
physiologically-realistic responses that are similar to theoretically-idealised 
physiological responses. 
In conclusion, the originality of this work is that it is the first time in which 
a parametric study of the control mechanism of bone remodelling under 
mechanical stimulus has been performed in the field of bone remodelling. 
This work will further the understanding of mechanical bone remodelling. 
The identified control mechanisms are able to help develop combined 
pharmacological and mechanical therapies to treat bone loss diseases such 
as osteoporosis. 
Chapter 6: Bone Remodelling under Pulsed Electro-magnetic 
Fields 
PEMF devices have been widely used in clinics to treat non-union fracture 
or accelerate bone fracture recovery. From a control mechanism 
perspective, it is quite likely that there are several control mechanisms 
working simultaneously in bone remodelling under PEMF; however, the 
precise underlying mechanisms are still elusive. In this chapter, the 
computational system biology method is used to model bone remodelling 
under PEMF at the cellular level, mathematically based on experimental 
findings and mathematical advances. An extensive parametric study of the 
control mechanism based on this model is then conducted. 
6.1 Model Development 
6.1.1 PEMF's Effects on Bone Remodelling 
The RANK/RANKL/OPG signalling pathway between osteoblasts and 
osteoclasts, PTH and the dual action of TGF-J3 is diagrammed in Figure 4.1. 
The 'convergence hypothesis' states that the activities of the resorptive and 
anti-resorptive agents 'converge' at the level of these two mediators, whose 
final ratio controls the degree of osteoclast differentiation, activation, and 
apoptosis [33]. 
PEMF applies its effects on bone cells partly through this pathway, and this 
concept is supported by a number of studies. In an in vitro study [77], a 
PEMF with a frequency of 15 Hz (1 G [0.1 mT]; electric field strength 2 
mV/cm) was applied to neonatal mouse calvarial bone cell cultures for 14 
days. The results demonstrated that PEMF stimulation significantly 
increased the osteoblasts' proliferation. The OPG expression was up-
regulated and the RANKL concentration was down-regulated, compared to 
the control group. In another study [135], researchers investigated the 
effect of PEMF with parameters modified from clinical bone stimulator 
devices and concluded that OPG might be a potential intermediary 
involved in the interplay between PEMF stimulation and osteoclastogenesis. 
Where appropriate, PEMF intensities could either promote or suppress 
OPG expressions in the osteoblastic lineage. In addition, the osteogenesis 
effect of PEMF was accompanied by the decrease of RANKL. The latest 
research also demonstrated that PEMF induces cells in the osteoblast 
lineage to express OPG [136]. 
Additionally, several studies have demonstrated that PEMF causes 
osteoblasts to produce other paracrine factors, including transforming 
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growth factor beta-1 (TGF-pl), prostaglandin E2 (PGE2) and bone 
morphogenetic protein-2 [137-139]. Moreover, macrophage colony-
stimulating factor (M-CSF) has been shown to decrease after PEMF 
exposure [135] and bone morphogenetic protein-2, -4, -5 was found to 
increase in osteoblasts after PEMF application [140, 141]. However, these 
observations were not consistent in the literature; as a result, these factors 
are not included in the effects of PEMF on bone remodelling in this study's 
model. 
PEMF stimulation, in comparison with drug administration, is able to 
produce a local concentration of growth factors synthesis, without any 
systemic side effects. However, it is important to keep in mind that, as with 
a drug, the dosage of physical stimulus is fundamental if positive effects on 
osteogenesis are to be produced. The biological effects of PEMF 
stimulation depend not only on the length of treatment time, but also on the 
signal characteristics such as intensity, waveform, frequency and length of 
the signal [142]. Research [143] found that PEMF is the most responsive, 
compared with other waveforms such as rectangular electro-magnetic fields 
(REMF), triangular electro-magnetic fields (TEMF) and sinusoidal electro-
magnetic fields (SEMF) in terms of their effects on the proliferation and 
differentiation effects on osteoblastic cells. 
With regard to the different types of PEMF, Bassett et al. [144] propose 
that single pulse is better than burst pulsed PEMF stimulation on 
osteoporosis prevention and non-union fracture healing, whereas burst 
pulsed PEMF stimulation had better effects on bone fracture healing 
acceleration. The study [145] examined the response of osteoblast-like cells 
to a PEMF stimulus, mimicking that of a clinically available device, using 
four protocols of the timing of the stimulus, each conducted over three days. 
Protocol one stimulated the cells for eight hours each day, protocol two 
stimulated the cells for 24 hours on the first day, protocol three stimulated 
the cells for 24 hours on the second day and protocol four stimulated the 
cells 24 hours on the third day. In terms of proliferation and differentiation 
of the cells compared with the control group, no clear trend was observed 
between the four protocols. 
Intensity of the PEMF is also an important factor, as data from [135] 
demonstrated that PEMF with different intensities could regulate 
osteoclastogenesis, bone resorption, OPG, RANKL and M-CSF 
concentrations in marrow culture system. Specifically, in this experiment, 
the author used three different electric field intensities of PEMF fields 
(4.8|LiV/cm, 8.7 jiV/cm, 12.2 jaV/cm) and observed that the recruitment of 
osteoclast-like cells was inhibited by approximately 33% and increased by 
approximately 10% when electric field intensities of PEMF were 4.8 
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jj.V/cm and 12.2 jiV/cm respectively. No significant differences at all time 
points were observed compared with the control group. 
6.1.2 Mathematical Model 
The schematic diagram of the mathematical model structure of bone 
remodelling under PEMF is illustrated in Figure 6.1. 
In the cell population dynamics model, this study included three cell 
populations (see osteoblastic and osteoclastic lineages in Figure 4.1) into 
model equations including OBP, OBA and OCA. Uncommitted 
osteoblastic progenitors (OBU) and osteoclastic precursors (OCP) work as 
reservoirs whereby the cells will differentiate into functional cells such as 
osteoblasts and osteoclasts respectively. Their numbers are much larger 
than the functional cells OBP, OBA or OCA. As a result, OBU and OCP 
are assigned a very large constant compared with other cell numbers in the 
model (i.e. OBU=OCP=lxlO"2 pM). 
Similar to [20] and the author's previous work [34, 88], the Hill equation is 
used to describe the activation and repression of the receptor-ligand 
interactions. In biochemistry, the Hill equation is used to describe the 
fraction of the macromolecule saturated by a ligand as a function of the 
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ligand concentration; it is used in determining the degree of cooperativity 
of the ligand binding to the enzyme or receptor. 
Figure 6.1: Schematic diagram of the mathematical model structure of PEMF stimulated bone 
remodelling at the cellular level 
It was originally formulated by Hill in 1910 [120] to describe the sigmoidal 
02 binding curve of haemoglobin: 
0 
t (6.1) 
KJ + L" K/ + I! 
where 0 is the fraction of ligand binding sites filled, L is the ligand 
concentration, Kd is the apparent dissociation constant derived from the 
law of mass action, KA is the ligand concentration producing half 
occupation and n is the Hill coefficient. 
In cell biology, cell responses such as differentiation, proliferation and 
apoptosis are all related to various ligand-receptor reactions of which some 
are stimulatory and others are inhibitory [20]. In modelling cell responses, 
the Hill equation is often used to describe the molecular input function. The 
activation (act) and repression (rep) forms of the Hill equation [121] for the 
production rate of a new cell or molecule are [20]: 
/ ( * • ) - / > M f t f j (6.2) 
1 + — 
m 
(6.3) 
where x* is the active form of concentration, x is a ligand that governs the 
production of a cell or molecule (z ) through binding to its receptor on cell, 
(5 is the maximal production rate of z, and K] and K2 are activation and 
repression coefficients. This thesis has already assumed that the Hill 
coefficient equals one. 
For convenience, here and later in the chapter, the abbreviated forms for 
the factors involved in the corresponding formulation have been used. As 
in Figure 1, this study used OBU for uncommitted osteoblastic progenitors, 
OBP for osteoblastic precursors, OBA for mature osteoblast, OCP for 
osteoclast precursor and OCA for active osteoclasts, RL for RANKL, RK 
for RANK and T{3 for TGF-(3. OPG and PTH remain unchanged. 
The equations governing the evolution of the number of osteoblastic and 
osteoclastic cells in each maturation stage are simply balance equations [6], 
which means that each cell stage is fed by an entering flow and is emptied 
by the outgoing flow of differentiated or apoptotic cells (see Figure 1). As a 
result, utilising Figure 6.1 and based on the formulation in [20], the bone 
cell population dynamics can be formulated as follows: 
^ = Dobu • OBU • - Dobp • OBP • (6.4) 
^ = DosP • OBP • n f j p - Aoba • OBA 
= DOCP • OCP • URJa OCP - Aoca , OCA • Wfct OCA 
= j y j • [OBA (t) - OBA(O)]- kres • [OCA ( / ) - OCA (0)] 
(6.5) 
(6.6) 
(6.7) 
where subscript 'cell' in the input functions represents the cell 
type that a specific molecule binds to, and 'molecule' denotes the ligand 
involved in a particular cell response. DOBU is the differentiation rate of 
uncommitted OB progenitors, DOBP is the differentiation rate of osteoblastic 
precursors, Doa> is the differentiation rate of preosteoclasts, AOBA is the rate 
of elimination of OBA and A^ is the rate of elimination of OCA. BV 
represents bone volume in percentage (%), and kfor and kres are the relative 
bone formation and bone resorption rates respectively. The simulation 
starts from a so-called 'steady-state' whereby BV is 100%, dBV/dt = 0 
correspondingly, OBA(t) is OBA(0) and OCA(t) is OCA (0). Equations (6.4) 
to (6.6) transform into Equations (6.8) to (6.10): 
0=dOBU • n ZOBU - DOBP • OBP (0) • N%Z (6.8) 
0 = DOBP • OBP (0) • NT£ OBP - AOBA • OBA{0) (6.9) 
0 = DocP- n%IOCP -AOCA-ocA(o)-n 
TP 
act,OCA (6.10) 
By solving equations (6.8) to (6.10), the initial values of the model 
variables in Table 6.1 can be obtained. 
Table 6.1: Initial values of the model variables. 
Symbol Unit Value 
OBA(O) pM 0.2126991130e-
3 
OBP(O) pM 0.8986869185e-
5 
OCA(O) pM 0.2769166993e-
3 
In the model, there are two different time scales: a short time scale is used 
to describe the receptor-ligand reactions such as RANK-RANKL, OPG-
RANKL and TGF-p with its receptor; and a long time scale is required to 
capture the cell number changes such as OBP, OBA and OCA. Note that 
the receptor-ligand reaction is much faster than the changes in cell numbers; 
therefore, a quasi-steady state assumption is used in the model to describe 
the receptor-ligand reactions. 
Bone matrix is the largest source of TGF-P in the body [108]. TGF-P, 
growth factors and specific components embedded in the bone matrix are 
released by osteoclasts during bone resorption [109]. The effect of TGF-P 
on osteoblasts is bi-directional, depending upon the state of maturation of 
the osteoblasts [6]. On one hand, TGF-P has the potential to stimulate 
osteoblast recruitment, migration and proliferation of osteoblast precursors 
(meaning OBPs in this model) [109]. On the other hand, TGF-p inhibits 
terminal osteoblastic differentiation into OB As [31]. In this model, it is 
assumed that the release rate of TGF-P from the bone matrix is constant. 
Using the short time scale and a quasi-steady state assumption the 
expression of TGF-P is [20]: 
a • KOCA + STn Tp= ^ TJ- (6.11) 
Tp 
STp is a source/sink term for TGF-P, a is the TGF-P content stored in bone 
matrix, Kres is the relative rate of bone resorption and bTft is the rate of 
degradation of TGF-p. Consequently, the activation and repression forms 
of TGF-P can be obtained by substituting Equation (6.11) into Equations 
(6.2) and (6.3): 
UTP 
* rtt-t 
T p (6.12) 
nT/? 11 f,'n am 
\+T/3/KD2rp 
(6.13) 
nT/? T/? (6.14) 
K D 3 , T / ? 
KDX Tp is the activation coefficient related to TGF-P binding on OBU, Kin Tp 
is the repression coefficient related to TGF-P binding on OBP and Km rp is 
the activation coefficient of TGF-P binding on OCA. Applying the law of 
mass action [6] used to describe the reactions of receptors and 
corresponding ligands, the formulations, including PTH with its receptor, 
RANKL with OPG and RANKL with RANK, can be found in the author's 
previous work [34]. 
In this model, PTH is a regulator of RANKL and OPG production. The 
assumption is that PTH endogenous production is constant and 
PTHmax»PTH and PTH binding to its receptors on OBP and OB A is the 
same, to obtain PTH concentration and its according activation and 
repression functions as [20]: 
PTH = Ppth+PpthA0 mi (6.15) 
PTH 
act,OBP 
PTH (6.16) n 
K D4,PTH + PTH 
PTH 
rep,OBA 1 + PTH IK Dil,TH 
(6.17) 
where ppw is the synthesis rate of systemic PTH, Ppmd(t) represents an 
external PTH dosing term, DPTH is the rate of degradation of PTH, KD4 PTH 
is the activation coefficient for RANKLeff on OBP related to PTH binding 
and KD5 pm is the repression coefficient for OPG production related to PTH 
binding on OB A. 
As stated previously, it has already been concluded that PEMF stimulates 
the production of OPG expressed in OBA and inhibits the expression of 
RANKL in OBP, based on experimental observations (see Section 6.1.1). 
OPG and RANKL are the only two factors that are considered to be 
regulated by PEMF stimulation and modelled in the model. The systemic 
hormone PTH down-regulates OPG production in OBA [34]. Therefore, 
based on [20], the OPG concentration can be expressed as: 
OPG = Popg ' OBA • (nf6 
•p.OBA 
POPG • OBA • ( n + Fopg (I, f , t, w)) 
OPGmm 
PTH (6.18) 
where poPG is the production rate of OPG per OB A, F0PG(l,f,t,w) is the 
influence of PEMF on OPG secretion characterised by its intensity, 
frequency, time and waveform, POPGd(t) is an external OPG administration 
term, DOPG is the rate of degradation of OPG and OPGmm is the maximum 
possible OPG concentration. In addition, PEMF inhibits RANKL 
expression in OBP and PTH up-regulates the RANKL 'effective carrying 
capacity' of OBP [34]. Building on [20] the concentration of RANKL can 
be obtained: 
RL = 
R • OBP • UPM RL K J U r 1 1 act,OBP 
KMMOPG KA2,RL " R K 
f^mP- w)+p„d(t) 
M • OBP • Frl ( I , / , w ) + Drl- R^ • OBP • nZh, 
TH 
,OBP Y 
(6.19) 
Ru is the maximum RANKL on OBP, KAhRl is the association binding 
constant RANKL-OPG, KA2 RL is the association binding constant RANKL-
RANK, f j i is the production rate of RANKL per OBP, FI>L(l,f,t,w) is the 
effect of PEMF on RANKL production characterised by its intensity, 
frequency, time and waveform, P ^ (/) is an external RANKL 
administration term and D^ is the rate of degradation of RANKL. Then, 
the activation function of RANKL on differentiation of osteoclast precursor 
cells OCP can be obtained using Equations (6.2) and (6.19): 
ItiflBHil (6-2°) 
KD6,RL + K L 
KD6RL is the activation coefficient related to RANKL binding on OCP. All 
the model parameters and their values can be found in Appendix C. 
6.2 Numerical Investigation of the Model 
Bone remodelling is an important biological system when it comes to bone 
fracture healing, non-union fracture and bone diseases such as osteoporosis. 
It is executed by coordinated activities of osteoclastic cells and osteoblastic 
cells in BMUs. The coupling between osteoclastic cells and osteoblastic 
cells is facilitated by the RANK/RANKL/OPG pathway, together with the 
systemic hormone PTH and transforming growth factor TGF-(3. PEMF 
devices are used clinically to promote bone healing especially non-union 
fracture but relatively little is known about the mechanisms involved. This 
chapter proposes a mathematical model to simulate the PEMF's effect on 
bone remodelling at the cellular level, which would help to better 
understand the underlying mechanisms. Here, this study solved the ODEs 
(6.4) to (6.7) numerically, using Matlab and plotted a series of graphs about 
the concentration dynamics of OPG, RANKL, cell populations of OBA, 
OCA and OBP, and bone volume, as can be observed in Figures 6.2-6.5, 
respectively. Note that the parameter values have been obtained from the 
models that this model is based on [20] and the author's previous work [34, 
88], 
The effects of PEMF on bone remodelling are characterised by its intensity, 
frequency, waveform and application time. According to the study [145], 
the timing of the PEMF stimulation does not affect the bone cell 
development, which is different from the bone remodelling under 
mechanical stimulus. In this numerical investigation, the specific parameter 
values of PEMF were chosen from the widely used PEMF devices in 
clinics [146] and this set of parameter values is the only one used in this 
study's model. Consequently, it is assumed that the PEMF effects on bone 
remodelling, specifically OPG or RANKL, in this model do not change 
(represented by two different constants Fopa and F^ in the model) 
throughout the simulation (three months). 
The concentration dynamics of OPG during the three-month PEMF 
application is simulated in Figure 6.2. Consistent with experimental 
observations, the OPG concentration increases during the first ten days 
simulation. Surprisingly, the concentration of OPG keeps dropping from 
the 10th day in simulation. For the reason that most in vitro experiments 
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were performed within two weeks, there is no available experimental data 
to compare with. The pattern of the OPG concentration might be explained 
by the fact that because of the PEMF's stimulus effect, OPG concentration 
increases in the short period after the PEMF's application, and then the 
binding of OPG with RANKL catches up as the bone remodelling occurs. 
More OPG are consumed than produced by osteoblast cells; as a result, 
OPG concentration drops until the end of the simulation. 
Figure 6.3 shows the RANKL concentration dynamics during the three-
month PEMF application. As can be observed from the graph, within two 
weeks (which is the time scale of most in vitro experiments), the RANKL 
concentration drops, compared with the initial value. However, it was not 
expected that the RANKL concentration would significantly increase 
immediately after the simulation began, followed by a dramatic decrease 
and the maintenance of a similar level throughout the rest of the simulation. 
A possible reason for this development pattern is that the number of 
preosteoblast cells that produce RANKL is increased by the PEMF's 
stimulus effect on the proliferation of bone marrow mesenchymal stem 
cells [34] immediately after the application of PEMF. Then, the inhibitory 
effect of PEMF on the OBP takes over and this overall trend is maintained 
until the end of the simulation. 
The cell population dynamics of OBA, OCA and OBP can be observed in 
Figure 6.4. As expected, the OBA and OBP populations rise and OCA 
decreases in the first two weeks of the simulation, which is consistent with 
experimental observations. Due to the coupling effect between OCA and 
OBA, the OBA population starts to decrease after it peaks and continues to 
decrease until the end of simulation while maintaining a higher 
concentration than OCA, which accounts for the continuing growth of bone 
volume in Figure 6.5. 
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Figure 6.2: OPG concentration dynamics during three-month P E M F application 
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Figure 6.5: Bone volume percentage dynamics during three-month PEMF application 
6.3 Parametric Study of Control Mechanism of Bone Remodelling 
under PEMF 
In this section, based on the mathematical model developed above, an 
extensive parametric study will be performed, investigating model 
parameters related to fundamental cell behaviours such as differentiation 
and apoptosis, in order to identify putative control mechanisms for 
physiologically reasonable bone remodelling under PEMF. 
The functional outputs of the bone remodelling system, such as bone loss 
or gain, or homeostasis, are executed by BMUs whereby osteoclasts absorb 
bone mineral in bone matrix and activated osteoblasts lay down the newly 
formed bone. The BMU acts as a mediator mechanism, bridging individual 
cellular activity to whole bone morphology [25], which is sensitive to any 
changes in its microenvironment. As a result, it is expected that any 
modification to the component of BMU will have a significant effect on its 
output behaviour. 
From a control theory perspective, one can always argue that there must be 
several control mechanisms working simultaneously in the complex bone 
remodelling system under PEMF, governing BMU's response to changes in 
its microenvironment by modifying differentiation or apoptosis rates of 
bone cells. This paper will apply perturbations to the bone remodelling 
system under PEMF (which is in a steady state) by down- and up-
regulating its parameters in random combination groups of five 
differentiation and apoptosis rate parameters: DFobu, DFacp, DFobp, Aoba and 
Aoca. In this case, each parameter in each group (groups of one, two, three, 
four and finally all five parameters at one time) could be up- or down-
regulated. Using the simple combination theory, the total number of 
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permutation can be calculated, which is 242 = ^ ^ - 2 ' . Then, in order to 
investigate the system behaviour for a wide range of changes, the 
exponentially changed factor (1.5") is now applied to each of the five 
differentiation and apoptosis rate parameters, whereby the exponent 
exranges from -10 to 10 in step increases of 0.5. The assessment of each of 
the parameter combinations to the system behaviour is chosen as the 
responses of bone volume, which are sampled on the 90th day to stand for 
the maximum change. Using Matlab (see the Matlab code in Appendix 
D.2), all 242 graphs can be plotted. Then, summarising all the plots of bone 
volume versus variation of exponent ex, it is found that there are three 
subsets of curves, which are plotted in Figure 6.6. 
Figure 6.6a and Figure 6.6b demonstrate an exponential increase and 
decrease of bone volume respectively, for increasing the model parameter 
exponentially (exponent ex from -10 to 10). This type of behaviour is 
considered as physiologically unrealistic from a biological perspective and 
obtained for quite a large range of model parameter combinations. 
Conversely, Figure 6.6c represents the other extreme, whereby only minor 
changes of bone volume occur during the entire range of parameter 
variation. These three types of response curves are excluded from further 
analysis because they do not provide an effective control mechanism for 
bone volume. 
In [20] the 'idealised' regulatory response by functionally active BMUs is 
discussed. As mentioned previously, the bone remodelling system starts 
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from a steady state in which it can be identified that ABV = 0, and 
concentrations of various hormones and growth factors cause initial values 
of differentiation and apoptosis rates in BMUs. In order to respond to 
minor changes in concentrations, it is expected that BMUs should be rather 
insensitive to these fluctuations. Therefore, from Figure 5.2, point A can be 
recognised as the threshold concentration, which means any change of 
model parameter underneath A causes no change in bone volume. In 
addition, a region around the usual operation status of BMUs should be 
found with relatively small gradients of changes in bone volume in 
response to changes in differentiation rates (regions C—D and D—E in 
Figure 5.2), with larger gradients for larger changes in differentiation rates 
(region E-F in Figure 5.2). It is expected that this response in bone volume 
change will remain limited if the differentiation rates increase significantly 
(region further after point F in Figure 5.2) because the unlimited rise in 
bone volume is not physiologically realistic. Conversely, it is expected that 
the rate of bone volume change would also decrease in a limited manner if 
the differentiation rates decrease significantly. In fact, physiologically, it is 
reasonable for the bone volume change to be zero for extremely small 
differentiation rates. Additionally, it can be observed from Figure 5.2 that 
point F marks the maximum change in bone volume (AB max). Since point 
A is the maximum concentration that does not lead to further modifications 
of bone volume, there must be a transition region from point C to A, which 
is characterised by point B, the lowest value of bone volume. 
Having found a potential 'ideal response curve', a search for the response 
curves that may meet these requirements can now begin. Encouragingly, a 
small number of curves have been identified that possess similarity to the 
idealised response curve. Table 6.2 summarises all the parameter 
combinations that produce idealised response curves. In Figure 6.7, the 
physiologically-realistic response curve is plotted, which corresponds to the 
parameter permutation involving three parameters ( AOBA , AOCA , AOST =-/+/+) 
and is similar to the idealised response curve shown in Figure 5.2. 
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Figure 6.6: Physiological unrealistic changes of BMC and BFE versus combined changes of model 
parameter |1.5"10- 1.5+l0)/>: (a) exponential bone growth, (b) exponential bone decrease and (c) 
slight changes of bone, (p is the parameter value) 
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Figure 6.7: Typical physiologically realistic fluctuations of bone volume with combinations of 
parameter change 
Table 6.2: Summary of parameter combinations that lead to controlled remodelling process. The 
variation with '+' represents parameter increase and '-' represents parameter decrease 
Number of 
parameters in a 
combination 
Combinations of 
differentiation and apoptosis 
rates 
Variation of 
each parameter 
2 n /A OBP' OBA +/+ 
2 n 1 A ^OCP' OST +/-
2 A 1A OBA' OCA -/+ 
3 DOBP / Aoha / A(X-a 
3 n / A / A OBP ' OBA ' nOCA -1-1+ 
3 n / A / A OBP | ^OBA P ^osr +1-1+ 
3 A / A / A OBA ' OCA ' OST -1+1+ 
4 DOBP ' Dqcp / Aoba / Aoca 
4 DOBP ' DQCP ' Aoba / A(X:a 
4 Ft 1 A 1 A / A OBP ' ™OBA ' -"OCA ' OST 
5 D0BU / Dobp / Dqcp / Aoba / Aosr 
5 F) I D 1 A 1 A 1 A OBU ' OBP ' OBA ' OCA 5 rlOST 
5 n / n / A / A / A OBP ' •OCP ' OBA f. OCA ' ^OST 
5 n / n / A / A / A OBP ' ^OCP ' OBA ' OCA * OST 
6.4 Summary 
In this chapter, a mathematical model of bone remodelling under PEMF at 
the cellular level was proposed based on experimental results and the 
author's previous work. This model incorporates the latest experimental 
findings through extensive literature review and summarises that PEMF 
applies its physiological effects via the RANK/RANKL/OPG pathway. 
Specifically, PEMF promotes the secretion of OPG and inhibits the 
production of RANKL, which suppresses the overall population of the 
osteoclasts that absorb bone minerals. Based on this model, the numerical 
investigation demonstrates the concentration dynamics of growth factors 
OPG and cytokines RANKL, and the population dynamics of OBA, OBP 
and OCA. More importantly, a parametric study of bone remodelling under 
PEMF was conducted in order to understand the control mechanism of 
bone remodelling at the cellular level under PEMF. 
This work will further the understanding of bone remodelling under PEMF 
and the indentified control mechanisms are able to help develop combined 
pharmacological and PEMF therapies to cure bone loss diseases such as 
osteoporosis. 
Chapter 7: Conclusions and Future Work 
7.1 Conclusions 
In this thesis, a mathematical framework of bone remodelling under 
mechanical stimulus and PEMF at the cellular level was developed by 
means of the computational system biology approach. 
This framework is comprised of three major models. The model of bone 
remodelling biological system at the cellular level that is able to simulate 
the anabolic effect of PTH when applied intermittently as a therapy to treat 
osteoporosis in clinical practice. Based on the first model, the factor of 
mechanical stimulus is taken into account in bone remodelling system at 
the cellular level. This model is then validated by comparison with 
experimental results, followed by the parametric study of the control 
mechanism of bone remodelling under mechanical stimulus at the cellular 
level. The last model is bone remodelling under PEMF at the cellular level, 
based on which the control mechanism is also investigated and a small 
number of possible control mechanisms are identified. 
In Chapter 3, a model of bone remodelling at the cellular level is developed 
for the first time that is able to simulate the anabolic effect of PTH when 
applied intermittently. This model integrates the latest progresses in the 
bone biology of remodelling and current advances in mathematics into the 
model, such as applying the law of mass action to describe the reactions of 
receptors and corresponding ligands, including PTH (P) with its receptor, 
RANKL with OPG, RANKL with RANK and IGF with its receptor. It also 
uses balance equations to govern the evolution of the number of principal 
cells in each compartment such as osteoblasts and osteoclasts. This model 
is developed as the platform of mathematical modelling of bone 
remodelling at the cellular level, based on which the factors such as 
mechanical stimulus and PEMF are taken into account and corresponding 
models are developed in Chapters 4, 5 and 6. 
In Chapter 4, the model of bone remodelling under mechanical stimulus 
was developed at the cellular level. A number of new features have been 
proposed for the first time in this field, such as: osteocyte being the 
physical mediator of mechanotransduction in bone remodelling under 
mechanical stimulus; three new rate equations describing changes of OST, 
NO and PGE2 being incorporated in the model; the effect of loading 
frequency on bone mechanosensitivity being investigated; the influence of 
the number of loading cycles during a loading day and the recovery of bone 
mechanosensitivity between two loading bouts as well as during the whole 
loading period being investigated; and the Hill equation being extended to 
two ligands binding to the same cell. The good agreement between the 
simulations and the experimental results is very encouraging, and indicates 
the correct understanding of the mechanical bone remodelling at the 
cellular level. 
In Chapter 5, based on the work in Chapter 4, the parametric study of 
mechanical bone remodelling model was conducted in order to understand 
the control mechanism of mechanical bone remodelling at the cellular level. 
Consequently, an extensive parametric study investigating model parameter 
space related to cell differentiation and apoptosis, which describes the 
fundamental cell lineage behaviours, was performed to investigate such a 
scenario. After analysing all of the 728 permutations of the six model 
parameters, a small number of parameter combinations that are able to 
cause physiologically realistic responses were successfully identified. 
The originality of this work is that it is the first time that a parametric study 
of the control mechanism of bone remodelling under mechanical stimulus 
has been performed in the field of bone remodelling. This work will further 
the understanding of mechanical bone remodelling and the identified 
control mechanisms are able to help develop combined pharmacological 
and mechanical therapies to treat bone loss diseases. 
In Chapter 6, a mathematical model of bone remodelling under PEMF at 
the cellular level was proposed based on experimental results and the 
author's previous work. This model incorporates the latest experimental 
findings through extensive literature review and summarises that PEMF 
applies its physiological effects via the RANK/RANKL/OPG pathway. 
Specifically, PEMF promotes the secretion of OPG and inhibits the 
production of RANKL, which suppresses the overall population of 
osteoclasts that absorb bone minerals. Based on this model, the numerical 
investigation demonstrates the concentration dynamics of growth factors 
OPG and cytokines RANKL, and the population dynamics of OBA, OBP 
and OCA. More importantly, parametric study of bone remodelling under 
PEMF was performed in order to understand the control mechanism of 
bone remodelling at the cellular level under PEMF. 
The quantitative analysis performed using this mathematical framework 
will improve the understanding of bone remodelling, which is of great 
importance to human beings, especially the elder population in our society. 
Based on the identified possible control mechanisms of bone remodelling, 
some 'virtual therapies' could be designed and tested by in vitro and in vivo 
experiments. The experimentally proved therapies could become potential 
real therapies to treat bone loss diseases such as osteoporosis. 
7.2 Future Work 
Future work could focus on the following assumptions and limitations on 
which the proposed framework is based: 
• The bone remodelling initiated by mechanical stimuli starts by 
programmed death in osteocytes [134]. It is still not known what 
factors cause osteocyte death. In the model, the osteocyte death at the 
beginning of bone remodelling is not taken into account. 
• The amounts of uncommitted OBU and OCP are assumed very large, 
for which reason the numbers of OBU and OCP do not appear in the 
model. 
• In the numerical simulations, the RANK concentration is fixed and 
this assumption could be relaxed in a future study. 
• The hypothesis that PTH endogenous production is considered as 
constant and no further regulated in the framework . 
• The framework is based on the so-called 'convergence hypothesis' 
that all the activities of resorptive or anti-resorptive agents converge 
at the level of RANKL and OPG through which the final effects are 
achieved. More factors could be introduced into the bone remodelling 
system in order to account for their effects that are supported by 
experimental observations. 
• The change in bone shape, namely the macroscopic bone surface 
remodelling, is not included here, which explains why there is no 
spatial distribution in the current model. 
• Coupling between mechanical and electro-magnetic bone remodelling 
because of piezoelectricity of bone is assumed minimal in the thesis, 
further experimental and theoretical research could be performed to 
verify this assumption. 
• Further experimental verification of the bone-remodelling model 
under PEMF could be conducted in the future. 
Appendix A 
Model's Parameters [6] 
Symbol Unit Valve Description 
Cs pM 5 x 10~3 Value of C to get half differentiation flux 
Da Day"1 0.7 
Rate of osteoclast apoptosis caused 
by TGF-p 
dB Day"1 0.7 
Differentiation rate of responding 
osteoblasts 
DC pM Day"1 2.1xl0"3 
Differentiation rate of osteoclast 
precursor 
Dr pM Day"1 7 x 10~4 
Differentiation rate osteoblast 
progenitors 
fo No dimension 0.05 Fixed proportion 
h pM Day"1 0-106 Rate of administration of RANKL 
lo pM Day"1 0-106 Rate of administration of OPG 
Ip pM Day"1 0-106 Rate of administration of PTH 
K pM 10 Fixed concentration of RANK 
k; pM"1 Day"1 10"2 Rate of OPG-RANKL binding 
k2 Day"1 10 Rate of OPG-RANKL unbinding 
k3 pM"1 Day"1 5.8X10"4 Rate of RANK-RANKL binding 
K Day"1 1.7 xlO"2 Rate of RANK-RANKL unbinding 
K pM"1 Day"1 0.02 
Rate of PTH binding with its 
receptor 
K Day"1 3 Rate of PTH unbinding 
B Day"1 0.189 Rate of elimination of AOB 
K pmol/pmol cells 3xl06 
Maximum number of RANKL 
attached on each cell surface 
o Day"1 0.35 Rate of elimination of OPG 
4 pmol day" /pmol cells 2xl05 Minimal rate of production of OPG per cell 
kp day"1 86 Rate of elimination of PTH 
rL pM day"1 103 
Rate of RANKL production and 
elimination 
Sp pM day"1 250 Rate of synthesis of systemic PTH 
Rs pM 5 x 10~2 
Value of R to get half differentiation 
flux 
ml % cell"1 d"1 122 Average rate of bone resorbed per day per AOC 
m2 % cell"1 d"1 195 Average rate of bone formed per day per AOB 
Appendix B 
Parameter values and descriptions (most parameter values are from [6, 20] 
except otherwise indicated) 
Symbol Unit Value Description 
OBU pM/day 7 x 10~4 
Differentiation rate of uncommitted OB 
progenitors 
DQBP pM/day 5.348 Differentiation rate of preosteoblasts 
DOCP pM/day 2.1 xlO"3 Differentiation rate of preosteoclasts 
A 
OBA pM/day 1.890x10"' Rate of elimination of OBA 
AXA pM/day 7.000 xlO"1 Rate of elimination of OCA 
Aysr pM/day 3.1xl0"2 Rate of elimination of OST [66, 67] 
D\JP pM 4.545 xlO - 3 Activation coefficient related to TGF-(3 binding on OBU 
K-D2JP pM 1.416xl0"3 Repression coefficient related to TGF-(3 binding on OBP 
K-D3JP pM 4.545 xl0~3 Activation coefficient of TGF-P binding on OCA 
KD4,PTH pM 1.500xl0 2 Activation coefficient for RANKLeff on OBP related to PTH binding 
D5,PTH pM 2.226 xlO"1 Repression coefficient for OPG production related to PTH binding on OBA 
pM 1.500xl0 2 Activation coefficient related to RANKL binding on OCP 
D1 ,NO pM 1.573x10 Activation coefficient for OPG production on OBA related to NO [66, 67] 
KDS,NO pM 2.189x10 Repression coefficient for RANKL production on OBP related to NO [66, 67] 
KD9,P2 pM 3.674 Activation coefficient for OBU differentiation related to PGE2 [66, 67] 
RK pM 1x10 Unchanged concentration of RANK 
RRL « 3 x l 0 6 Maximum RANKL on OBP 
PPTH pM/cell 2 .5x l0 2 Synthesis rate of systemic PTH 
PRL pM/cell 1.684x10" Production rate of RANKL per OBP 
POPG pM/cell 1.464xl0 8 Production rate of OPG per OBA 
DPTH pM/day 8.6x10 Rate of degradation of PTH 
P* pM/cell 1.013x10 Rate of degradation of RANKL 
D()PC pM/cell 3.5x10"' Rate of degradation of OPG 
DM pM/cell 1x10° Rate of degradation of TGF-f3 
M pM/cell lxlO3 Rate of degradation of NO [66, 67] 
DP2 pM/cell lxlO2 Rate of degradation of T PGE2 [66, 67] 
TP - 0.5 
Relative influence of TGF-|3 binding in 
OBU differentiation 
P2 - 0.5 
Relative influence of PGE2 in OBU 
differentiation 
JR 
PTH - 0.7 Relative influence of PTH binding in production of OPG in OBA 
NO - 0.3 
Relative influence of NO in production of 
OPG in OBA 
IS pM"1 1 x 10~3 Association binding constant RANKL-OPG 
IS 
A2.RL pM"1 3.412xl0 - 2 Association binding constant RANKL-RANK 
OPGMM pM 2 x l 0 8 Maximum possible OPG concentration 
a % 1 TGF-(3 content stored in bone matrix w day" 1 Relative rate of bone resorption 
Kfor day" 1.571 Relative rate of bone formation 
day"1 1.552x10 Relative rate of bone turnover [66, 67] 
T OBA pM/day 0.15 
Rate of trapped OBA in bone matrix [66, 
67] m pM/day 2 x l 0 4 Secretion rate of NO by osteocytes [66, 67] 
KP1 pM/day lxlO2 Secretion rate of PGE2 by osteocytes [66, 67] 
T acc day 24 
time constant describing the rate at which 
accommodation takes place [128] 
T h 6 a time constant [127] 
Appendix C 
Parameter values and descriptions [17, 26] 
Symbol Unit Value Description 
OBIJ pM/day 7 x 10"4 
Differentiation rate of uncommitted OB 
progenitors 
DQBP pM/day 5.348 Differentiation rate of preosteoblasts 
DOCP pM/day 2.1x10~3 Differentiation rate of preosteoclasts 
A OBA pM/day 1.890x10"' Rate of elimination of OBA 
AXA pM/day 7.000x10"' Rate of elimination of OCA 
A)ST pM/day 3.1 xlO"2 Rate of elimination of OST 
IS Ol,/"/? pM 4.545 xlO"3 Activation coefficient related to TGF-p binding on OBU 
^D2,T/3 pM 1.416xl0"3 Repression coefficient related to TGF-|3 binding on OBP 
D3,T/J pM 4.545 xlO"3 Activation coefficient of TGF-p binding on OCA 
gp 
D4,PTH pM 1.500xl02 Activation coefficient for RANKLeff on OBP related to PTH binding 
JS 
D5,PTH pM 2.226x10"' 
Repression coefficient for OPG production 
related to PTH binding on OBA 
K-D6,RL pM 1.500xl02 Activation coefficient related to RANKL binding on OCP 
pM 1.573x10 Activation coefficient for OPG production on OBA related to NO 
D&,NO pM 2.189x10 Repression coefficient for RANKL production on OBP related to NO 
D9,P2 pM 3.674 Activation coefficient for OBU differentiation related to PGE2 
RK pM 1x10 Unchanged concentration of RANK 
m - 3xl0
6 Maximum RANKL on OBP 
Ppth pM/cell 2.5xl02 Synthesis rate of systemic PTH 
Prl pM/cell 1.684x10" Production rate of RANKL per OBP 
POPG pM/cell 1.464xl08 Production rate of OPG per OBA 
Dpth pM/day 8.6x10 Rate of degradation of PTH 
Drl pM/cell 1.013x10 Rate of degradation of RANKL 
Dqpc, pM/cell 3.5x10"' Rate of degradation of OPG 
Drp pM/cell 1x10° Rate of degradation of TGF-P 
m pM/cell lxlO3 Rate of degradation of NO H pM/cell lxlO2 Rate of degradation of T PGE2 
k 0.5 Relative influence of TGF-|3 binding in A.RP OBU differentiation 
IT 0.5 Relative influence of PGE2 in OBU P2 differentiation 
I 0.7 Relative influence of PTH binding in PTH production of OPG in OBA 
k 0.3 Relative influence of NO in production of NO OPG in OBA 
IS 
IS~A\,RL pM"1 lxlO-3 Association binding constant RANKL-OPG 
^A2,RL pM"1 3.412xl0"2 Association binding constant RANKL-RANK 
OPGMM pM 2xl08 Maximum possible OPG concentration 
a % 1 TGF-p content stored in bone matrix 
Kes day1 1 Relative rate of bone resorption 
KFOR day"1 1.571 Relative rate of bone formation H day"1 1.552x10 Relative rate of bone turnover 
T OB A pM/day 0.15 Rate of trapped OBA in bone matrix 
KNO pM/day 2xl04 Secretion rate of NO by osteocytes 
KP2 pM/day lxlO2 Secretion rate of PGE2 by osteocytes 
Appendix D 
D.l Matlab Code of Parametric Study of Control Mechanism of Bone 
Remodeling under Mechanical Stimulus 
DG[rl] := 1.013el; 
DG[p2] := 3.; 
DG[no] := 0.7e2; 
DG[opg] := 3.5e-l; 
DG[Tbeta] := 1; 
DG[pth] := 8.6el; 
Tr[oba] :=.15; 
K[D1, Tbeta] :=4.545e-3; 
K[D2, Tbeta] := 1.416e-3; 
K[D3, Tbeta] := 4.545e-3; 
K[D4, pth] := 1.5e2; 
K[D5, pth] := 2.226e-l; 
K[D6, rl] := 1.306el; 
K[D7, no] := 1.573el; 
K[D8, no] := 2.189el; 
K[D9, p2] := 3.674; 
S[Tbeta] := 0; 
P[pth, d] j | 0; 
P[rl, d] 1 0 ; 
P[opg, d] := 0; 
RK := f | 
R[rl] := 3e6; 
beta[pth] := 2.5e2; 
beta[rl] := 1.684e4; 
beta[opg] := 1.464e8; 
Opgfmaxi] := 2e8; 
K[A1, rl] := le-3; 
K[A2, rl] := 3.412e-2; 
alpha := 1; 
B[res] := 1; 
B[form] := 24.876; 
tau 6; 
PR[no] := 0.35e5; 
PR[p2] := 0.25e3; 
T[rest] := 3; 
N 360; 
f :=2 ; 
AP := 3.2; 
kk[Tbeta] := .3; 
kk[p2] .7; 
kk[pth] := .7; 
kk[no] := .3; 
FEC := 12.52; 
T[acc] := 24; 
total := 1; 
with(combinat); 
paraindex := [1, 2, 3, 4, 5, 6]; 
for i to 6 do 
paracomb[i] := choose(paraindex, i); 
for j to factorial(6)/(factorial(6-i)*factorial(i)) do 
for k from 0 to 2Ai-l do 
paravalue := [0.7e-3, 5.348, 0.21e-2, .189, .7, 
0.31e-l]; 
for 1 to i do 
c[0, k] := k; 
c[l, k] := iquo(c[l-l, k], 2); 
b[l, k] := irem(c[l-l, k], 2); 
if b[l, k] = 0 then b[l, k] := -1 endif; 
indexnum w= paracomb[i][j][l]; 
paravalue [indexnum] :=paravalue[in 
dexnum]*1.5A(b[l, k]*pq); 
end do: 
DF[obu] := paravalue[l]; 
DF[obp] := paravalue[2]; 
DFfocp] := paravalue[3]; 
A[oba] := paravalue[4]; 
A[oca] := paravalue[5]; 
A[ost] := paravalue[6]; 
print(total, "DF[obu]=", DF[obu], "DF[obp]=", 
DF[obp], "DF[ocp]=", DF[ocp], "A[oba]=", A 
[oba], "A[oca]=", A[oca], "A[ost]=", A[ost]); 
TGF[beta] :=(alpha*B [res] *OCA(t)+S [Tbeta])/DG[Tbet 
a]; 
PI[Tbeta, act, obu] := 
TGF[beta]/(K[Dl,Tbeta]+TGF[beta]); 
PI[Tbeta, rep, obp] := l/(l+TGF[beta]/K[D2, Tbeta]); 
PI[Tbeta, act, oca] := TGF [beta]/(K[D3, 
Tbeta]+TGF[beta]); 
PTH := (beta[pth]+P[pth, d])/DG[pth]; 
PI[pth, act, obp] := PTH/(K[D4, pth]+PTH); 
PI[pth, rep, oba] := 1/(1+PTH/K[D5, pth]); 
PI [no, act, oba] := NO(t)/(K[D7, no]+NO(t)); 
PI [no, rep, obp] := l/(l+NO(t)/K[D8, no]); 
PI[p2, act, obu] := P2(t)/(K[D9, p2]+P2(t)); 
R[PFSS] := 2*Pi*AP*f; 
OPG := (beta[opg]*OBA(t)*(kk[pth]*PI[pth,rep, 
oba]+kk[no] * PI [no, act, oba])+P[opg, 
d])/(beta[opg] * OB A(t)*(kk[pth] * PI [pth, rep, 
oba]+kk[no]*PI[no,act,oba])/Opg[maxi]+DG[opg 
]); 
RL :=R[rl]* OBP(t)* PI [pth,act,obp] * (beta[rl] * OB 
P(t)*PI[no, rep, obp]+P[rl, d])/((l+K[Al, 
rl]*OPG+K[A2,rl]*RK)*(beta[rl]*OBP(t)*PI[no, 
rep,obp]+DG[rl]*R[rl]*OBP(t)*PI[pth, act, 
obp])); 
PI[rl, act, ocp] := RL/(K[D6, rl]+RL); 
eql :-diff(OBP(t),t)=DF[obu]*(kk[Tbeta]*PI[Tb 
eta, act, obu]+kk[p2]*PI[p2, act, obu])-
DF [obp] * OBP(t)* PI [Tbeta, rep, obp]; 
eq2 :=diff(OB A(t),t)=DF [obp] * OBP(t)* PI [Tbeta, 
rep, obp]-A[oba]*OBA(t); 
eq3 := diff(OST(t), t) = Tr[oba]*OBA(t)-
A[ost]*OST(t); 
eq4 := diff(OCA(t), t) = DF[ocp]*PI[rl,act,ocp]-
A[oca]*OCA(t)*PI[Tbeta, act, oca]; 
eq5 := diff(NO(t), t) 
PR[no]*R[PFSS]*OST(t)*(l-exp(-
T[rest]/tau))*ln(l+N)*ln(f+.5)*exp(-t/T[acc])-
DG[no]*NO(t); 
eq6 := diff(P2(t), t) 
PR[p2] * R[PF S S] * OST(t)* (1 -exp(-
T[rest]/tau))*ln(l+N)*ln(f+.5)*exp(-t/T[acc])-
DG[p2]*P2(t); 
eq7 := diff(BMC(t), t) - B[form]*(OBA(t)-
0.2126991130e-3)-B[res]*(C>CA(t)-
0.2769166993e-3); 
eq8 := diff(BFE(t), t) = diff(BMC(t), 
t)+FEC * sqrt(OB A(t)+OC A(t)); 
icsl := OBA(O) = 0.2126991130e-3, OST(O) = 
0.1029189256e-2, OBP(O) = 0.8986869185e-5, 
OCA(O) =0.2769166993e-3, 
NO(O) = 0, P2(0) 1 0, BMC(0) = 100,BFE(0) = 
100; 
ansl := dsolve({eql, eq2, eq3, eq4, eq5, eq6, eq7, 
eq8, icsl}, {BFE(t), BMC(t), NO(t), OBA(t), 
OBP(t), OCA(t), OST(t), P2(t)}, type = numeric, 
maxfun = 0, parameters - [pq]); 
plotcoordl := [seq([0, 0], i = 1 .. 41)]; 
plotcoord2 := [seq([0, 0], i = 1 .. 41)]; 
ii :=1; 
for qq from -10 by .5 to 10 do 
ansl (parameters = [qq]); 
plotcoordl [ii] :=[qq,rhs(ansl(100)[3 
])]; 
plotcoord2[ii] :=[qq,rhs(ans 1(100)[2 
])]; 
ii := ii+1; 
end do: 
results[total] :=plot([plotcoordl,plotcoord2],color = 
black, linestyle - [1, 3], legend = ["BMC-100th day", 
"BFE-100th day"], labels = ["Exponent"," [%]"], axes = 
boxed, labeldirections = [HORIZONTAL, 
VERTICAL]); 
total := total+1; 
end do: 
end do: 
end do: 
total := 1; 
with(combinat); 
paraindex := [1, 2, 3, 4, 5, 6]; 
for i to 6 do 
paracomb[i] := choose(paraindex, i); 
for j to factorial(6)/(factorial(6-i)*factorial(i)) do 
for k from 0 to 2Ai-1 do 
paravalue := [0.7e-3, 5.348, 0.21e-2, .189, .7, 
0.3 le-1]; 
for 1 to i do 
c[0, k] := k; 
c[l, k] := iquo(c[l-l, k], 2); 
b[l, k] := irem(c[l-l, k], 2); 
if b[l, k] = 0 then b[l, k] := -1 endif; 
indexnum := paracomb[i][j][l]; 
paravalue [indexnum] :=paravalue[in 
dexnum]* 1.5A(b[l, k]*pq); 
end do: 
DF[obu] := paravalue[l]; 
DF[obp] := paravalue[2]; 
DF[ocp] := paravalue[3]; 
A[oba] := paravalue[4]; 
A[oca] := paravalue[5]; 
A[ost] := paravalue[6]; 
print(total, "DF[obu]=", DF[obu], "DF[obp]=", 
DF[obp], "DF[ocp]=", DF[ocp], "A[oba]=", A 
[oba], "A[oca]=", A[oca], "A[ost]=", A[ost]); 
TGF[beta] :=(alpha*B[res]*OCA(t)+S[Tbeta])/DG[Tbet 
a]; 
PI[Tbeta, act, obu] := 
TGF[beta]/(K[Dl,Tbeta]+TGF[beta]); 
PI[Tbeta, rep, obp] := l/(l+TGF[beta]/K[D2, Tbeta]); 
PI[Tbeta, act, oca] := TGF[beta]/(K[D3, 
Tbeta]+TGF[beta]); 
PTH := (beta[pth]+P[pth, d])/DG[pth]; 
PI[pth, act, obp] := PTH/(K[D4, pth]+PTH); 
PI[pth, rep, oba] := 1/(1+PTH/K[D5, pth]); 
PI [no, act, oba] := NO(t)/(K[D7, no]+NO(t)); 
PI [no, rep, obp] := l/(l+NO(t)/K[D8, no]); 
PI[p2, act, obu] := P2(t)/(K[D9, p2]+P2(t)); 
R[PFSS] := 2*Pi*AP*f; 
OPG := (beta[opg] * OB A(t)* (kk[pth] * PI [pth,rep, 
oba]+kk[no]*PI[no, act, oba])+P[opg, 
d])/(beta[opg]*OBA(t)*(kk[pth]*PI[pth, rep, 
oba]+kk[no]*PI[no,act,oba])/Opg[maxi]+DG[opg 
]); 
RL :=R[rl]* OBP(t)*PI [pth,act,obp] *(beta[rl] * OB 
P(t)*PI[no, rep, obp]+P[rl, d])/((l+K[Al, 
rl]*OPG+K[A2,rl]*RK)*(beta[rl]*OBP(t)*PI[no, 
rep,obp]+DG[rl]*R[rl]*OBP(t)*PI[pth, act, 
obp])); 
PI[rl, act, ocp] := RL/(K[D6, rl]+RL); 
eq 1 :=diff(OBP(t),t)=DF[obu]*(kk[Tbeta]*PI[Tb 
eta, act, obu]+kk[p2]*PI[p2, act, obu])-
DF [obp] * OBP(t) * PI [Tbeta, rep, obp]; 
eq2 :=diff(OBA(t),t)=DF[obp]*OBP(t)*PI[Tbeta, 
rep, obp]-A[oba]*OBA(t); 
eq3 := diff(OST(t), t) = Tr[oba]*OBA(t)-
A[ost]*OST(t); 
eq4 := diff(OCA(t), t) =. DF[ocp]*PI[rl,act,ocp]-
A[oca]*OCA(t)*PI[Tbeta, act, oca]; 
eq5 := diff(NO(t), t) 
PR[no]*R[PFSS] * OST(t)* (1 -exp(-
T[rest]/tau))*ln(l+N)*ln(f+.5)*exp(-t/T[acc])-
DG[no]*NO(t); 
eq6 := diff(P2(t), t) 
PR[p2]*R[PFSS]*OST(t)*(l-exp(-
T[rest]/tau))* ln( 1+N)* ln(f+. 5 )* exp(-t/T[acc] )-
DG[p2]*P2(t); 
eq7 := diff(BMC(t), t) = B[form]*(OBA(t)-
0.2126991130e-3)-B[res]*(C)CA(t)-
0.2769166993e-3); 
eq8 := diff(BFE(t), t) = diff(BMC(t), 
t)+FEC* sqrt(OB A(t)+OC A(t)); 
icsl := OBA(0) = 0.2126991130e-3, OST(O) = 
0.1029189256e-2, OBP(O) = 0.8986869185e-5, 
OCA(O) =0.2769166993e-3, 
NO(O) = 0, P2(0) f 0, BMC(O) = 100,BFE(0) = 
100; 
ansl :®= dsolve({eql, eq2, eq3, eq4, eq5, eq6, eq7, 
eq8, icsl}, {BFE(t), BMC(t), NO(t), OBA(t), 
OBP(t), OCA(t), OST(t), P2(t)}, type = numeric, 
maxfun = 0, parameters -- [pq]); 
plotcoordl [seq([0, 0], i = 1 .. 41)]; 
plotcoord2 := [seq([0, 0], i = 1 .. 41)]; 
ii := 1; 
for qq from -10 by .5 to 10 do 
ansl (parameters = [qq]); 
plotcoord 1 [ii] :=[qq,rhs(ans 1 (100)[3 
plotcoord2[ii] :=[qq,rhs(ans 1 (100)[2 
])]; 
ii := ii+1; 
end do: 
results[total] :=plot([plotcoordl,plotcoord2],color = 
black, linestyle = [1, 3], legend = ["BMC-100th day", 
"BFE-lOOth day"], labels = ["Exponent"," [%]"], axes = 
boxed, labeldirections = [HORIZONTAL, 
VERTICAL]); 
total := total+1; 
end do: 
end do: 
end do: 
with(combinat); 
paraindex := [1, 2, 3, 4, 5, 6]; 
for i to 6 do 
paracomb[i] := choose(paraindex, i); 
for j to factorial(6)/(factorial(6-i)*factorial(i)) do 
for k from 0 to 2Ai-l do 
paravalue := [0.7e-3, 5.348, 0.21e-2, .189, .7, 
0.3 le-1]; 
for 1 to i do 
c[0, k] := k; 
c[l, k] := iquo(c[l-l, k], 2); 
b[l, k] := irem(c[l-l, k], 2); 
if b[l, k] = 0 then b[l, k] := -1 endif; 
indexnum := paracomb[i][j][l]; 
paravalue [indexnum] :=paravalue [in 
dexnum]* 1.5A(b[l, k]*pq); 
end do: 
DF[obu] := paravalue[l]; 
DF[obp] := paravalue[2]; 
DF[ocp] := paravalue [3]; 
A[oba] := paravalue[4]; 
A[oca] := paravalue[5]; 
A[ost] := paravalue[6]; 
print(total, "DF[obu]=", DF[obu], "DF[obp]=", 
DF[obp], "DF[ocp]=", DF[ocp], "A[oba]=", A 
[oba], "A[oca]=", A[oca], "A[ost]=", A[ost]); 
TGF[beta] :=(alpha*B [res] * OCA(t)+S [Tbeta])/DG[Tbet 
a]; 
PI[Tbeta, act, obu] := 
TGF[beta]/(K[Dl,Tbeta]+TGF[beta]); 
PI[Tbeta, rep, obp] := l/(l+TGF[beta]/K[D2, Tbeta]); 
PI[Tbeta, act, oca] := TGF[beta]/(K[D3, 
Tbeta]+TGF[beta]); 
PTH := (beta[pth]+P[pth, d])/DG[pth]; 
PI[pth, act, obp] |= PTH/(K[D4, pth]+PTH); 
PI[pth, rep, oba] := 1/(1+PTH/K[D5, pth]); 
PI [no, act, oba] := NO(t)/(K[D7, no]+NO(t)); 
PI[no, rep, obp] := l/(l+NO(t)/K[D8, no]); 
PI[p2, act, obu] := P2(t)/(K[D9, p2]+P2(t)); 
R[PFSS] 2*Pi*AP*f; 
OPG := (beta[opg] * OB A(t)* (kk[pth] * PI [pth,rep, 
oba]+kk[no]*PI[no, act, oba])+P[opg, 
d])/(beta[opg]*OBA(t)*(kk[pth]*PI[pth, rep, 
oba]+kk[no]*PI[no,act,oba])/Opg[maxi]+DG[opg 
]); 
RL :=R[rl] * OBP(t)*PI [pth,act,obp] * (beta[rl] * OB 
P(t)*PI[no, rep, obp]+P[rl, d])/((l+K[Al, 
rl] * OPG+K[A2,rl] * RK)*(beta[rl] * OBP(t)*PI [no, 
rep,obp]+DG [rl] * R[rl] * OBP(t)* PI [pth, act, 
obp])); 
PI[rl, act, ocp] := RL/(K[D6, rl]+RL); 
eql :=di ff(OBP(t),t)=DF [obu] * (kk[Tbeta] * PI [Tb 
eta, act, obu]+kk[p2]*PI[p2, act, obu])-
DF [obp] * OBP(t)*PI [Tbeta, rep, obp]; 
eq2 :=diff(OBA(t),t)=DF [obp] * OBP(t)* PI [Tbeta, 
rep, obp] - A [oba] * OB A(t); 
eq3 := diff(OST(t), t) = Tr[oba]*OBA(t)-
A[ost]*OST(t); 
eq4 := diff(OCA(t), t) = DF[ocp]*PI[rl,act,ocp]-
A [oca] * OC A(t)* PI [Tbeta, act, oca]; 
eq5 := diff(NO(t), t) 
PR[no] * R[PF S S] * OST(t)* (1 -exp(-
T[rest]/tau))*ln(l+N)*ln(f+.5)*exp(-t/T[acc])-
DG[no]*NO(t); 
eq6 := diff(P2(t), t) 
PR[p2] * R[PF S S] * OST(t)* (1 -exp(-
T[rest]/tau))* ln( 1 +N)*ln(f+.5)* exp(-t/T[acc])-
DG[p2]*P2(t); 
eq7 := diff(BMC(t), t) = B[form]*(OBA(t)-
0.2126991130e-3)-B [res] * (OC A(t)-
0.2769166993e-3); 
eq8 := diff(BFE(t), t) = diff(BMC(t), 
t)+FEC*sqrt(OBA(t)+OCA(t)); 
icsl := OBA(O) = 0.2126991130e-3, OST(O) = 
0.1029189256e-2, OBP(O) = 0.8986869185e-5, 
OCA(O) =0.2769166993e-3, 
NO(O) = 0, P2(0) = 0, BMC(O) = 100,BFE(0) * 
100; 
ansl := dsolve({eql, eq2, eq3, eq4, eq5, eq6, eq7, 
eq8, icsl}, {BFE(t), BMC(t), NO(t), OBA(t), 
OBP(t), OCA(t), OST(t), P2(t)}, type I numeric, 
maxfun = 0, parameters = [pq]); 
plotcoordl m [seq([0, 0], i = 1 .. 41)]; 
plotcoord2 := [seq([0, 0], i = 1 .. 41)]; 
ii := 1; 
for qq from -10 by .5 to 10 do 
ansl (parameters = [qq]); 
plotcoordl [ii] :=[qq,rhs(ansl(100)[3 
m 
plotcoord2[ii] :=[qq,rhs(ansl(100)[2 
])]; 
ii := ii+1; 
end do: 
results[total] :=plot([plotcoordl,plotcoord2],color gt 
black, linestyle = [1, 3], legend = ["BMC-100th day", 
"BFE-lOOth day"], labels = ["Exponent", " [%]"], axes = 
boxed, labeldirections = [HORIZONTAL, 
VERTICAL]); 
total := total+1; 
end do: 
end do: 
end do: 
D.2 Matlab Code of Parametric Study of Control 
Mechanism of Bone Remodeling under PEMF 
DG[rl] B 1.013*10; 
DG[opg] := 3.5*10A(-1); 
DG[Tbeta] := 1; 
DG[pth] := 8.6*10; 
Tr[oba] :=.15; 
K[D1, Tbeta] := 4.545* 10A(-3); 
K[D2, Tbeta] := 1.416*10A(-3); 
K[D3, Tbeta] := 4.545* 10A(-3); 
K[D4, pth] 1.5*10A2; 
K[D5, pth] := 2.226* 10A(-1); 
K[D6, rl] := 1.306*10; 
S[Tbeta] := 0; 
P[pth, d] := 0; 
P[rl, d] := 0; 
P[opg, d] := 0; 
RK := 1; 
R[rl] := 3*10A6; 
beta[pth] :=2.5*10A2; 
beta[rl] := 1.684* 10A4; 
beta[opg] := 1.464* 10A8; 
Opg[maxi] :=2*10 A 8; 
K[A1, rl] := 10A(-3); 
K[A2, rl] := 3.412* 10A(-2); 
alpha := 1; 
B[res] := 1; 
B[form] 1.571; 
F[opg] := 2; 
F[rl] := .5; 
total := 1; 
with(combinat); 
paraindex := [1, 2, 3, 4, 5]; 
for i to 5 do 
paracomb[i] := choose(paraindex, i); 
for j to factorial(5)/(factorial(5-i)*factorial(i)) do 
for k from 0 to 2Ai-l do 
paravalue := [0.7e-3, 5.348, 0.21e-2, .189, .7]; 
for 1 to i do 
c[0, k] # k; 
c[l, k] iquo(c[l-l, k], 2); 
b[l, k] J irem(c[l-l, k], 2); 
if b[l, k] = 0 then b[l, k] := -1 end if; 
indexnum := paracomb[i][j][l]; 
paravalue[indexnum] :=paravalue [indexnum]* 1.5 
*(b[l, k]*pq); 
end do: 
DF[obu] := paravalue[l]; 
DF[obp] := paravalue [2]; 
DF[ocp] := paravalue[3]; 
A[oba] := paravalue[4]; 
A[oca] := paravalue[5]; 
print(total, "DF[obu]=", DF[obu], MDF[obp]=", DF[obp], 
"DF[ocp]=", DF[ocp], "A[oba]-', A[oba], "A[oca]=", A[oca]); 
TGF[beta] := (alpha*B [res] *OCA(t)+S [Tbeta])/DG[Tbeta]; 
PIfTbeta, act, obu] §f TGF[beta]/(K[Dl, Tbeta]+TGF[beta]); 
PI[Tbeta, rep, obp] := l/(l+TGF[beta]/K[D2, Tbeta]); 
PIfTbeta, act, oca] := TGF[beta]/(K[D3, Tbeta]+TGF[beta]); 
PTH := (beta[pth]+P[pth, d])/DG[pth]; 
PI [pth, act, obp] := PTH/(K[D4, pth]+PTH); 
PI[pth, rep, oba] := 1/(1+PTH/K[D5, pth]); 
OPG :=(beta[opg]*OBA(t)*PI[pth,rep,oba]+P[opg,d])/(beta[o 
pg] * OB A(t)* PI [pth, rep, oba]/Opg[maxi]+DG[opg]); 
RL[eff] := R[rl]*OBP(t)*PI[pth, act, obp]; 
RL := R[rl]*OBP(t)*PI[pth, act, obp]*(beta[rl]*OBP(t)+P[rl, 
d])/(( 1 +K[Al,rl]*OPG+K[A2,rl]*RK)*(beta[rl]*OBP(t)+DG[ 
rl]*OBP(t)*PI[pth, act, obp])); 
PI[rl, act, ocp] := RL/(K[D6, rl]+RL); 
eql := diff(OBP(t), t) = DF [obu]* PI [Tbeta, act, obu]-
DF [obp] * OBP(t)* PI [Tbeta, rep, obp]; 
eq2 diff(OBA(t), t) = DF[obp]*OBP(t)*PI[Tbeta, rep, obp]-
A[oba]*OBA(t); 
eq3 := diff(OCA(t), t) = DF[ocp]*PI[rl, act, ocp]-
A[oca] * OC A(t)* PI [Tbeta, act, oca]; 
eq4 := diff(BV(t), t) = B[form]*(OBA(t)-0.2126991130e-3)-
B[res]*(OCA(t)-0.2769166993e-3); 
ics § OBP(O) = 0.8986869185e-5, OBA(O) = 0.2126991130e-
3, OCA(O) = 0.2769166993e-3, BV(0) = 100; ans := 
dsolve({eql, eq2, eq3, eq4, ics},{BV(t),OBA(t), OBP(t), 
OCA(t)}, type = numeric, maxfun = 0, parameters = [pq]); 
plotcoordl := [seq([0, 0], i = 1 .. 41)]; 
ii := 1; 
for qq from -10 by .5 to 10 do 
ans(parameters = [qq]); 
plotcoordl [ii] := [qq, rhs(ans(90)[2])]; 
ii := ii+1; 
end do: 
resultsftotal] := plot([plotcoordl], color = black, linestyle = 1, 
thickness = 2, legend = ["BV-90th day"], labels = ["Exponent", 
" Bone volume [%]"], axes = boxed, labeldirections = 
[HORIZONTAL, VERTICAL]); 
total := total+1; 
end do: 
end do: 
end do: 
with(combinat); 
paraindex := [1, 2, 3, 4, 5]; 
for i to 5 do 
paracomb[i] := choose(paraindex, i); 
for j to factorial(5)/(factorial(5-i)*factorial(i)) do 
for k from 0 to 2Ai-1 do 
paravalue := [0.7e-3, 5.348, 0.21e-2, .189, .7]; 
for 1 to i do 
c[0, k] := k; 
c[l, k] := iquo(c[l-l, k], 2); 
b[l, k] := irem(c[l-l, k], 2); 
if b[l, k] = 0 then b[l, k] := -1 end if; 
indexnum := paracomb[i][j][l]; 
paravalue[indexnum] :=paravalue[indexnum]* 1.5 
> [ 1 , k]*pq); 
end do: 
DF[obu] := paravalue[l]; 
DF[obp] := paravalue [2]; 
DF[ocp] := paravalue[3]; 
A[oba] := paravalue[4]; 
A[oca] := paravalue[5]; 
print(total, "DF[obu]=", DF[obu], "DF[obp]=", DF[obp], 
"DF[ocp]=", DF[ocp], "A[oba]=", A[oba], "A[oca]=", A[oca]); 
TGF[beta] := (alpha*B[res]*OCA(t)+S[Tbeta])/DG[Tbeta]; 
PI[Tbeta, act, obu] := TGF[beta]/(K[Dl, Tbeta]+TGF[beta]); 
PIfTbeta, rep, obp] := l/(l+TGF[beta]/K[D2, Tbeta]); 
PI[Tbeta, act, oca] := TGF[beta]/(K[D3, Tbeta]+TGF[beta]); 
PTH := (beta[pth]+P[pth, d])/DG[pth]; 
PI[pth, act, obp] := PTH/(K[D4, pth]+PTH); 
PI[pth, rep, oba] := 1/(1+PTH/K[D5, pth]); 
OPG :=(beta[opg] * OB A(t)* PI [pth,rep,oba]+P [opg,d] )/(beta[o 
pg]*OBA(t)*PI[pth, rep, oba]/Opg[maxi]+DG[opg]); 
RL[eff] := R[rl]*OBP(t)*PI[pth, act, obp]; 
RL := R[rl] * OBP(t)* PI [pth, act, obp]*(beta[rl]*OBP(t)+P[rl, 
d])/((1 +K[ A1 ,rl] * OPG+K[A2,rl]*RK)*(beta[rl]*OBP(t)+DG[ 
rl] * OBP(t)* PI [pth, act, obp])); 
PI[rl, act, ocp] := RL/(K[D6, rl]+RL); 
eql := diff(OBP(t), t) = DF [obu]* PI [Tbeta, act, obu]-
DF[obp]*OBP(t)*PI[Tbeta, rep, obp]; 
eq2 := diff(OBA(t), t) - DF[obp]*OBP(t)*PI[Tbeta, rep, obp]-
A[oba]*OBA(t); 
eq3 := diff(OCA(t), t) = DF[ocp]*PI[rl, act, ocp]-
A [oca] * OC A(t) * PI [Tbeta, act, oca]; 
eq4 := diff(BV(t), t) = B[form]*(OBA(t)-0.2126991130e-3)-
B [res] *(QCA(t)-0.2769166993e-3); 
ics := OBP(O) 10.8986869185e-5, OBA(O) = 0.2126991130e-
3, OCA(O) 1 0.2769166993e-3, BV(0) = 100; ans := 
dsolve({eql, eq2, eq3, eq4, ics},{BV(t),OBA(t), OBP(t), 
OCA(t)}, type = numeric, maxfun = 0, parameters = [pq]); 
plotcoordl := [seq([0, 0], i = 1 .. 41)]; 
ii := 1; 
for qq from -10 by .5 to 10 do 
ans(parameters = [qq]); 
plotcoordl [ii] := [qq, rhs(ans(90)[2])]; 
ii := ii+1; 
end do: 
results[total] := plot([plotcoordl], color = black, linestyle = 1, 
thickness = 2, legend = ["BV-90th day"], labels = ["Exponent", 
" Bone volume [%]"], axes = boxed, labeldirections = 
[HORIZONTAL, VERTICAL]); 
total := total+1; 
end do: 
end do: 
end do: 
with(combinat); 
paraindex := [1, 2, 3, 4, 5]; 
for i to 5 do 
paracomb[i] := choose(paraindex, i); 
for j to factorial(5)/(factorial(5-i)*factorial(i)) do 
for k from 0 to 2Ai-1 do 
paravalue := [0.7e-3, 5.348, 0.21e-2, .189, .7]; 
for 1 to i do 
c[0, k] := k; 
c[l, k] := iquo(c[l-l, k], 2); 
b[l, k] := irem(c[l-l, k], 2); 
if b[l, k] = 0 then b[l, k] -1 end if; 
indexnum := paracomb[i][j][l]; 
paravalue[indexnum] :=paravalue[indexnum]* 1.5 
> [ 1 , k]*pq); 
end do: 
DF[obu] := paravalue[l]; 
DF[obp] := paravalue[2]; 
DF[ocp] := paravalue [3]; 
A[oba] := paravalue[4]; 
A[oca] := paravalue[5]; 
print(total, "DF[obu]=", DF[obu], "DF[obp]=", DF[obp], 
MDF[ocp]=", DF[ocp], "A[oba]=", A[oba], "A[oca]=", A[oca]); 
TGF[beta] := (alpha* B [res] * OCA(t)+S [Tbeta] )/DG[Tbeta]; 
PI[Tbeta, act, obu] := TGF[beta]/(K[Dl, Tbeta]+TGF[beta]); 
PI[Tbeta, rep, obp] := l/(l+TGF[beta]/K[D2, Tbeta]); 
PI[Tbeta, act, oca] i TGF[beta]/(K[D3, Tbeta]+TGF[beta]); 
PTH := (beta[pth]+P[pth, d])/DG[pth]; 
PI[pth, act, obp] := PTH/(K[D4, pth]+PTH); 
PI[pth, rep, oba] := 1/(1+PTH/K[D5, pth]); 
OPG :=(beta[opg]*OBA(t)*PI[pth,rep,oba]+P[opg,d])/(beta[o 
pg] * OB A(t) * PI [pth, rep, oba]/Opg[maxi]+DG[opg]); 
RL[eff] := R[rl]*OBP(t)*PI[pth, act, obp]; 
RL := R[rl]*OBP(t)*PI[pth, act, obp]*(beta[rl]*OBP(t)+P[rl, 
d])/((l+K[Al,rl]*OPG+K[A2,rl]*RK)*(beta[rl]*OBP(t)+DG[ 
rl] * OBP(t)* PI [pth, act, obp])); 
PI[rl, act, ocp] := RL/(K[D6, rl]+RL); 
eql := diff(OBP(t), t) * DF [obu] * PI [Tbeta, act, obu]-
DF [obp] * OBP(t)* PI [Tbeta, rep, obp]; 
eq2 := diff(OBA(t), t) = DF [obp] *OBP(t)* PI [Tbeta, rep, obp]-
A[oba]*OBA(t); 
eq3 := diff(OCA(t), t) = DF[ocp]*PI[rl, act, ocp]-
A[oca]*OCA(t)*PI[Tbeta, act, oca]; 
eq4 := diff(BV(t), t) = B[form]*(OBA(t)-0.2126991130e-3)-
B [res] * (OC A(t)-0.2769166993e-3); 
ics := OBP(O) 10.8986869185e-5, OBA(O) = 0.2126991130e-
3, OCA(O) = 0.2769166993e-3, BV(0) = 100; ans := 
dsolve({eql, eq2, eq3, eq4, ics},{BV(t),OBA(t), OBP(t), 
OCA(t)}, type = numeric, maxfun = 0, parameters = [pq]); 
plotcoordl := [seq([0, 0], i = 1 .. 41)]; 
ii := 1; 
for qq from -10 by .5 to 10 do 
ans(parameters = [qq]); 
plotcoordl [ii] := [qq, rhs(ans(90)[2])]; 
ii := ii+1; 
end do: 
results[total] := plot([plotcoordl], color §F black, linestyle = 1, 
thickness = 2, legend - ["BV-90th day"], labels = ["Exponent", 
" Bone volume [%]"], axes = boxed, labeldirections = 
[HORIZONTAL, VERTICAL]); 
total := total+1; 
end do: 
end do: 
end do: 
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